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ABSTRACT  
   
Glioblastoma (GBM) is the most common primary brain tumor with an incidence 
of approximately 11,000 Americans. Despite decades of research, average survival for 
GBM patients is a modest 15 months. Increasing the extent of GBM resection increases 
patient survival. However, extending neurosurgical margins also threatens the removal of 
eloquent brain. For this reason, the infiltrative nature of GBM is an obstacle to its 
complete resection. The central hypothesis of this dissertation is that targeting genes and 
proteins that regulate GBM motility, and developing techniques that safely enhance 
extent of surgical resection, will improve GBM patient survival by decreasing infiltration 
into eloquent brain regions and enhancing tumor cytoreduction during surgery. Chapter 2 
of this dissertation describes a gene and protein; aquaporin-1 (aqp1) that enhances 
infiltration of GBM. In chapter 3, a method is developed for enhancing the diagnostic 
yield of GBM patient biopsies which will assist in identifying future molecular targets for 
GBM therapies. In chapter 4, an intraoperative optical imaging technique is developed for 
improving identification of GBM and its infiltrative margins during surgical resection. 
This dissertation aims to target glioblastoma infiltration from molecular and cellular 
biology and neurosurgical disciplines. In the introduction; 1. A background of GBM and 
current therapies is provided. 2. A protein that decreases GBM survival is discussed. 3. 
An imaging modality utilized for improving the quality of accrued GBM patient samples 
is described. 4. An overview of intraoperative contrast agents available for neurosurgical 
resection of GBM, and discussion of a new agent for intraoperative visualization of GBM 
is provided. 
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CHAPTER 1 
INTRODUCTION 
 New brain tumors are diagnosed in more than 40,000 Americans each year . They 
are the second most common cause of cancer death up to age 35, with a slight peak 
among children between 6 and 9 years old; but these tumors are most common among 
middle-aged and older adults. About half of brain tumors are primary - i.e. their origin is 
intracranial, the remaining tumors are metastases to the brain (Schneider, Mawrin et al. 
2010).   
 Initial efforts to characterize brain tumors were made by Rudolph Virchow in the 
mid-nineteenth century. His work identified gliomas as a major class of brain tumors 
(Ferguson and Lesniak 2005). In1926 Percival Bailey and Harvey Cushing published a 
landmark paper classifying gliomas into 13 unique groups. Bailey later refined this 
classification into 10 groups. These initial studies showed that each type of brain tumor 
produced a unique prognosis (Bailey 1985, Ferguson and Lesniak 2005). 
 
Cell Types 
 Glial cells provide the support structure of the brain. These cells include 
oligodendrocytes, microglia, ependymal cells, and astrocytes. Oligodendrocytes modulate 
salutatory conduction in the central nervous system (CNS) through axonal myelination. 
Microglia are the macrophages of the brain, and respond to pathogens within the CNS. 
Ependymal cells line ventricles within the CNS and are the source of cerebrospinal fluid. 
Astrocytes provide structural and biochemical support, are involved in synaptic 
transmission, and respond to brain injuries (Kandel, Schwartz et al. 2000, McCoy and 
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Sontheimer 2010, Clarke and Barres 2013). Glial cell interaction is currently a heavily 
studied field in neuroscience.  
 
Brain Tumors 
 Primary brain tumors, tumors that arise from cells within the brain, can be 
classified as benign or malignant. Non-diffuse tumors, such as low grade meningiomas, 
schwannomas, and pituitary adenomas typically grow slowly and discreetly. These 
tumors can often be removed by surgery. In contrast, malignant tumors such as high 
grade gliomas diffusely invade the brain (Louis, Deutsches Krebsforschungszentrum 
Heidelberg. et al. 2007). These tumors present a challenge to surgical resection and 
detection of their infiltrative elements (Roberts, Valdes et al. 2012). 
 Clinical prognostic factors for gliomas include tumor grade, patient age, and 
performance status (DP Byar 1983, Mahaley, Mettlin et al. 1990, Daumas-Duport 1992, 
Barker, Prados et al. 1996). The most important current criteria for diagnosis and 
treatment of human infiltrative gliomas are histologic subtype and grade. Subtype is 
based on visual and molecular similarity of neoplastic cells to normal cells in the central 
nervous system. Thus, astrocytomas look like cells of astrocytic lineage and express 
markers linked to normal astrocytes, and oligodendrogliomas look like cells of 
oligodendroglial lineage, etc. Histologic grade is scored by the degree of endothelial 
hyperplasia, necrosis, nuclear atypia, and mitotic activity with low grade tumors 
exhibiting cellular atypia. High grade gliomas, which tend to be the most infiltrative, 
exhibit 3 to 4 of these criteria (Daumas-Duport, Scheithauer et al. 1987, Daumas-Duport, 
Scheithauer et al. 1988, Daumas-Duport 1992). 
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Current Therapy 
 Glioblastoma is the most common primary brain tumor. Average GBM survival is 
12-15 months. Less than 30% of the 27,000 patients diagnosed with GBM each year will 
survive beyond 2 years (Schneider, Mawrin et al. 2010, Teodorczyk and Martin-Villalba 
2010). In 1980, the post-resection median survival of GBM patients was six months. If 
chemotherapy and radiation were included at the time the median survival increased to 
approximately twelve months (Salcman 1980). Decades of focused research have 
improved GBM characterization and diagnosis. However, current median survival for 
GBM after aggressive treatment is a modest 12-15 months (Georges, Zehri et al. 2014). 
Thirty years of research has only increased survival approximately 3 months.  
 Standard GBM treatment is surgical resection followed by radiation and treatment 
with the alkylating agent, temozolomide (Hegi, Diserens et al. 2005). GBM resection is 
aimed at maximal safe resection as aggressive surgery prolongs patient survival. 
However, in some cases, GBM may reside in critical regions that preclude resection 
(Sanai and Berger 2008, Sanai and Berger 2009, Sanai and Berger 2011, Sanai, Polley et 
al. 2011, Bloch, Han et al. 2012). Regardless of completeness of resection, infiltrative 
cells always remain following surgical cytoreduction leading to recurrence (Di, Mattox et 
al. 2010). Controlling and/or targeting infiltrative tumor cells may improve the extent of 
surgical resection and improve patient survival. 
 Temozolomide (TMZ), a chemotherapeutic agent introduced in 1999, has 
increased GBM patient survival approximately 3 months. This cytotoxic agent, once 
converted to its active form in the alkaline tumor environment, damages DNA by 
methylating DNA guanine bases at the N7, N3, and O-6 positions. TMZ’s cytotoxic 
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effects are mediated by its methylation of guanine at the O6 position (O6-MeG). This 
prohibits DNA strand elongation by a persistent mismatch of O6-MeG to thymine rather 
than cystine. Missmatch repair results in a persistent O6-MeG in the template strand and 
futile cycling of DNA repair which leads to cessation of cell replication and death. 
However, some tumor cells express MGMT; an enzyme that can efficiently repair O6-
MeG.  Tumors with this enzyme respond poorly to TMZ (Zhang, Stevens et al. 2012, 
Hart, Garside et al. 2013). Infiltrative tumor cells may also be less responsive to TMZ 
since these cells have decreased mitotic activity and may be further away from the 
alkaline tumor environment (Wolf, Agnihotri et al. 2011, Zhang, Stevens et al. 2012). 
Therefore, agents specifically targeting infiltrative cells may be required in addition to 
standard chemotherapeutics. 
 Radiation is an anti-neoplastic therapeutic typically used with chemotherapy. 
Radiation damages DNA in mitotically active cells. Cancer cells are less capable of 
dealing with DNA damage and eventually decrease in mitotic activity or die. Radiation 
therapy relies on generation of free radicals in oxygen-rich environments. Infiltrative 
cells undergo a change known as the Warburg effect. Once infiltrative cells migrate away 
from vasculature their oxygen access diminishes and they switch from aerobic to 
anaerobic metabolism (Warburg effect).This altered environment and metabolism may 
attenuate the effects of radiation on infiltrative tumor cells (Wolf, Agnihotri et al. 2010, 
Wolf, Agnihotri et al. 2011).   
 Surgical resection, TMZ therapy, and radiation are the current standard of care for 
GBM patients (Schneider, Mawrin et al. 2010, Sanai, Polley et al. 2011, Hart, Garside et 
al. 2013). However, infiltrative tumor cells may be less receptive to all these therapeutic 
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approaches by evading resection and altering physiologic properties targeted by 
chemotherapy and radiation (Wolf, Agnihotri et al. 2010, Wolf, Agnihotri et al. 2011, 
Mattox, Li et al. 2012). Controlling GBM infiltration may improve patient outcomes by 
increasing the efficacy of current GBM therapies. 
 
GBM Infiltration 
The infiltrative nature of GBM allows tumor regions to evade surgical resection 
(Orringer, Lau et al. 2012) and may attenuate the effectiveness of tumor-specific 
therapeutic agents (Wolf, Agnihotri et al. 2011). Identifying genes and proteins that 
regulate tumor cell motility may improve efficacy of current therapeutics by providing 
additional clinical targets for GBM therapy. Inhibiting tumor infiltration may also allow 
GBM to be treated as a chronic disease by controlling its damage to surrounding brain.  
Secondly, developing methods to identify infiltrative cells during surgical resection could 
lead to a greater extent of tumor resection and increased patient survival (Sanai and 
Berger 2008, Sanai, Polley et al. 2011, Bloch, Han et al. 2012). 
 
Aquaporin-1 
We recently identified aquaporin-1expression (AQP1 = gene, aqp1 = protein) as a 
predictor of GBM patient survival. A clinical nine gene predictive indicator of GBM 
survival suggests AQP1 is independently prognostic (Colman, Zhang et al.). AQP1 
expression is linked to increased motility in normal (McCoy and Sontheimer) and 
neoplastic glial cells (McCoy and Sontheimer 2007). Our experiments with cultured 
human GBM cells reveal that AQP1 enhanced motility without significantly altering cell 
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growth or proliferation. Previously, the physiological role of aqp-1 expression in GBM 
was unknown. Chapter 2 of this thesis addresses a gap in knowledge related to aqp-1’s 
role in GBM motility.  
 Aquaporins (AQPs) are a family of mammalian transmembrane proteins. They 
were first identified by Peter Agre in 1991 while studying red blood cells. CHIP28, later 
named Aquaporin 1, was the first aquaporin discovered.  These small channel proteins 
(267 amino acids, 30kDA) are mostly known for water transport. We now know of 13 
aquaporin proteins (aqp). Aqps 1-6 have been identified to transport water. AQPs 7-13 
have been reported to transport water and glycerol (Gonen and Walz 2006).   
 Aquaporins are tetramers composed of 4 identical monomers. Each monomer 
contains two repeating elements that contain an asparagine-proline-alanine (NPA) motif. 
The NPA motifs align once the monomer folds and effectively form a water channel. The 
channel forms an hour-glass shape. At its narrowest point, the channel transports 
individual water molecules (Agre 2006).  
 
Aquaporin-1 and Cell Motility 
 Several aquaporins - AQP-1, 3, 4, 5, and 9 – have been linked to cell motility 
(Loitto, Karlsson et al. 2009).  AQP1 is overexpressed in migrating endothelial cells and 
AQP3 increases motility of keratinocytes in the skin and corneal epithelial cells in the 
eye. Normally, AQP1 is only expressed in ependymal cells within the CNS. However, 
AQP1 and AQP4 are both overexpressed in migrating reactive astrocytes responding to 
traumatic injury.  AQP1 is also linked to motility in neoplasms of the breast, CNS, and 
lung (Verkman, Hara-Chikuma et al. 2008).   
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 The mechanism of AQP1-mediated motility in GBM and other neoplasms is 
unknown. Proposed mechanisms of AQP-1 mediated motility include: 1) Rapid water 
flux may promote cell morphological changes during migration through narrow spaces, 
2) Water flux through AQP1 may generate a propulsive force to facilitate directional 
movement, 3) Local increases in hydrostatic pressure may detach the cell membrane from 
the cytoskeleton resulting in repolymerization of the cytoskeleton to support the 
protruded membrane. However, these mechanisms have not been rigorously tested.  
Assembly of aquaporins’ 4 subunits creates a central pore in the protein that transports K+ 
ions (Yool and Campbell 2012). Hypotheses of AQP1 mediated motility have focused on 
water transport, while the functional role of AQP1’s potassium ion transport in motility 
has been generally overlooked.   Increased potassium conductance has been shown to 
enhance the motility of GBM cells (Catacuzzeno, Aiello et al. 2011). If AQP1 
overexpression similarly alters K
+
 conductance, its role in cell motility may be 
independent of water transport.    
 
Aquaporin-1 Water Transport Inhibition 
 Independent study of aqp1-mediated water transport or ion transport on cell 
motility is not possible with current aqp1 inhibitors. The commonly used aqp1 inhibitors 
in basic science are mercurial compounds such as HgCl2 and tetraethylammonium 
(TEA). Unfortunately, these agents are toxic and/or nonspecific for independent testing 
of AQP1’s water transport function (Brooks, Regan et al. 2000, Farina, Rocha et al. 
2011).  
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 HgCl2 inhibits AQP1-facilitated water transport by forming a covalent bond with 
its cysteine 189 residue. C189 is in the pore forming region of loop E, and binding of 
HgCl2 to this region effectively blocks the water channel (Yool, Brown et al. 2010).  
Unfortunately, HgCl2 is cytotoxic.  It inhibits enzymatic processes, blocks sulfur 
oxidation processes, enzymatic processes involving B6 and B12, alters cytochrome C 
processes, and affects cellular mineral levels of Ca, Mg, Zn, and Li. In humans it can 
cause allergic, immune, and autoimmune responses. Therefore, independent study of 
aqp1-mediated water transport is problematic with HgCl2 (Sutton and Tchounwou 2006). 
 TEA may be a less toxic alternative to Hg for inhibiting AQP1 water transport. 
This compound reversibly binds Tyrosine 186 in AQP1. TEA appears more specific to 
AQP1 than Hg and may be less cytotoxic. However, this agent also blocks some K+ 
channels. This precludes its use as a specific agent targeting the water transport function 
of AQP1 without influencing K+ conductance (Brooks, Regan et al. 2000). 
 Independent of water transport, aqp1 promotes cation conductance when 
expressed in oocytes (Boassa, Stamer et al. 2006). Targeted substitution of asparagine for 
glutamate in the first transmembrane portion of AQP1 has generated a water-
impermeable aqp-1 mutant (e17n). Tested in oocytes, e17n failed to produce water flux, 
but produced cation conductance. Though specific inhibitors of AQP1-mediated water 
transport are under development (Antonio Frigeri 2007), their antineoplastic activity has 
not been rigorously studied. Non-water permeating aqp1 mutants, such as e17n, allow for 
immediate study of specific inhibition of aqp1’s water channel.  
 Chapter 2 of this thesis investigates the relationship between AQP1 water 
transport and GBM invasion in vitro and in vivo. Our results suggest aqp1 harbors a 
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undocumented function that promotes tumor cell motility independent of water transport. 
This suggests novel inhibitors of aqp1-mediated GBM motility must target regions 
outside of the water channel. 
 
Cellular Screening of Biospecimens 
 Our work identifying AQP1 as a prognostic factor was made possible by studying 
biobanked samples of human GBM. During surgical resection of tumors, tumor samples 
are immediately frozen and stored for future diagnostic or analytical use (Vaught, 
Henderson et al. 2012). The necrotic nature of GBM is an obstacle for this technique, as 
many biobanked samples do not contain the cellularity to appropriately re-capitulate the 
features of the original tumor.  Incorporated into neuro-oncology studies, necrotic tissues 
could produce erroneous results for researchers (Botling and Micke 2011, Lim, 
Dickherber et al. 2011, Basik, Aguilar-Mahecha et al. 2013). In clinical trials, GBM 
patient responses are correlated with molecular characteristics of the participants’ 
tumors.  Therefore, storage of necrotic tissue could be detrimental to collecting useful 
information during a clinical trial. A method for screening biospecimens prior to storage 
could improve the quality of tissue samples collected for research and clinical use. 
 
Confocal Reflectance Microscopy 
 Confocal reflectance microscopy (CRM) is an optical imaging modality that can 
sample thick tissue without the application of contrast agents. CRM generates contrast by 
raster-scanning a laser across a sample and collecting back-scattered photons after they 
have passed through a confocal aperture. Similar to fluorescence confocal microscopy, 
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this technique can generate thin optical sections from examined tissues. However, CRM 
does not excite fluorophores or cause a detectable Stokes shift (Wirth, Snuderl et al. 
2012, Georges, Zehri et al. 2014). Therefore, CRM introduces a small fraction of 
potentially damaging laser energy into sampled tissue and does not require application of 
exogenous contrast agents.  
 In chapter 3, we evaluate the effectiveness of CRM for determining the cellularity 
of GBM tissue samples prior to biobanking. Secondly, we test if this imaging technique 
alters the molecular characteristics of examined tissue. We believe CRM will provide 
means for increasing the diagnostic yield of GBM biospecimens by assessing their 
cytoarchitecture prior to biobanking. 
 
Visualizing Surgical Margins 
 Extent of glioblastoma surgical resection and survival are directly correlated. 
Maximum survival benefit is achieved at greater than 98% tumor volume reduction 
(Lacroix, Abi-Said et al. 2001, Tonn, Thon et al. 2012). However, high degrees of 
resection are difficult to achieve due to the infiltrative nature of GBM and the 
Neurosurgeon’s goal of preserving eloquent brain. A means for intraoperative 
examination of glioma tissue at a cellular level could increase tumor cytoreduction by 
allowing immediate detailed differentiation between tumor and normal brain (Sanai 
2012). Neurosurgeons are equipped with MRI, ultrasonography, and macroscopic 
fluorescence guided-surgery, but these technologies do not provide visualization of 
detailed infiltrative tumor margins. In chapter 4, we show the use of a novel contrast 
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agent can immediately provide specific intraoperative visualization of astrocytic tumors, 
such as GBM, at the cellular level. 
 
Sulforhodamine 101 
 Advancing optical technologies such as a laser scanning confocal micropscopy 
(LSCM) may provide real time histopathological information of GBM in vivo and ex vivo 
(Foersch, Heimann et al. 2012). LSCM allows microscopic tissue analysis with cellular 
and subcellular detail. Contrast of morphological details is typically generated with the 
application of exogenous fluorescent dyes (Udovich, Besselsen et al. 2009).  This 
technology has recently been studied in the neurosurgical setting to improve resection by 
providing immediate histological assessment of tumor margins (Sanai, Eschbacher et al. 
2011). Currently, three fluorescent contrast agents are approved for in vivo neurosurgical 
applications, these include fluorescein sodium (FNa), indocyanine green (ICG), and 
aminolevulinic acid (5-ALA). Unfortunately, FNa and ICG only provide non-specific 
staining, and 5ALA photobleaches too quickly for cellular imaging (Mooney, Zehri et al. 
2014). The development of new fluorescent contrast agents that specifically stain 
astrocytic tumors could provide specific intraoperative diagnoses and allow better 
identification of the infiltrative margin of brain tumors. 
 Sulforhodamine 101 (SR101) is a red fluorescent contrast agent that rapidly labels 
astrocytes with glial fibrillary acidic protein (GFAP)-like specificity; the target for 
immunohistochemistry staining of astrocytes and astrocytomas (Berens, Bjotvedt et al. 
1993, Nimmerjahn, Kirchhoff et al. 2004). However, SR101 is capable of labeling 
astrocytic cells in minutes, whereas conventional GFAP staining requires a minimum of 
  12 
24 hours (Nimmerjahn and Helmchen 2012). SR101’s potential for neurosurgical use has 
not been studied. In chapter 4 of this dissertation, we hypothesized that if SR101 
similarly labels tumors of astrocytic lineage, such as GBM, it could provide a rapid 
alternative to GFAP for intraoperative identification of GBM and its infiltrative margins. 
Unlike fluorescein and indocyanine green, SR101 is capable of providing specific 
intracellular staining of astrocytic cells. Due to its strong quantum yield and resilience to 
photobleaching, SR101 can provide real-time visualization of astrocytic cells at the 
cellular level, which is not possible with 5-ALA.  
 In chapter 4 of this thesis, we aim to establish whether the selective staining of 
astrocytic tumors with SR101 is a reliable and reproducible method for rapidly 
identifying human astrocytoma cells in cell culture, animal models, and fresh human 
brain tumor biopsies. We hypothesize that combined use of live-cell imaging with SR101 
could provide a rapid method for identifying GBM and its infiltrative margins. 
 
Summary 
 Infiltrative tumor cells provide a challenge to the clinical and surgical treatment of 
GBM. This dissertation addresses a means for clinically targeting the infiltration of GBM 
by: 
1. Identifying AQP1 as a gene and protein that enhances the infiltration of GBM.   
2. Developing a GBM biospecimen screening technique that will aide in discovering 
future GBM molecular targets. 
3. Identifying a new GBM-specific contrast agent that can intraoperatively assess GBM 
and its margins.  
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 In chapter two, we study the role of AQP1 overexpression in GBM. We identify 
the prognostic role of this gene and protein from human biospecimens and test its 
physiological effects in cell culture and animal models of GBM. Next, we develop GBM 
cells expressing mutants of this protein to determine if its role in GBM cell migration is 
mediated by water transport. We find aqp1 overexpression can upregulate GBM cell 
motility independently of water transport. 
 In chapter three we recognize the current problem of over-sampling necrotic 
tissue in GBM biobanking. We test confocal reflectance microscopy as a means for 
screening GBM tissue prior to biobanking. We further evaluate the influence this imaging 
modality has on downstream molecular analysis of the GBM biospecimens. We find 
CRM can immediately differentiate cellular from non-cellular GBM biospecimens 
without altering their molecular characteristics. 
Lastly, in chapter four we identify a new intraoperative contrast agent that may assist the 
identification of GBM and tumor margins during resection. We test this contrast agent in 
cell culture, animal models of GBM, and fresh human ex vivo brain tumor biopsies. As a 
negative control, we also test this contrast agent on an animal model of central nervous 
system lymphoma and non-astrocytic human brain tumor biopsies. We find SR101 can 
provide intraoperative specific visualization of astrocytic tumors and their margins. 
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CHAPTER 2A 
AQUAPORIN 1 PREDICTS SURVIVAL OF MALIGNANT GLIOMA PATIENTS 
AND INCREASES GLIOMA CELL INVASIVENESS  
Glioblastoma (World Health Organization grade 4 glioma; GBM) are highly 
vascular, infiltrative tumors with 12-15 month median patient survival. Standard 
treatment is surgical resection, radiation and chemotherapy, but provides modest survival 
benefit.  Since GBM are infiltrative, local therapies do not remove all neoplastic 
elements, and appropriate therapeutic alternatives for infiltrative cells are not available. 
These studies address a potential therapeutic target, the water channel protein aquaporin 1 
(aqp1).  Literature suggests expression of the aquaporin 1 gene (AQP1) correlates 
negatively with patient survival, and links the protein to cell movement.  Our clinical data 
indicate AQP1 RNA and aqp1 protein are independently prognostic.  We developed ex 
vivo, and in vivo assays to model likely mechanisms underlying the clinical effects of 
AQP1. The results suggest that AQP1 decreases GBM patient survival by altering the 
motility of GBM, but not cell proliferation or survival.  Our results suggest that aqp1 
protein is a viable therapeutic target. 
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Introduction 
 
Malignant gliomas represent a treatment challenge for the neuro-oncology team.  
Patients with the most malignant and common glioma, World Health Organization (WHO) 
grade 4 or glioblastoma multiforme (GBM), most often die within 2 years of diagnosis, 
and fewer than 10% become long-term survivors (Stupp, Mason et al. 2005). Even when 
the surgeon achieves a gross total resection of tumor, microscopic residual cells nearly 
always remain.  Standard therapy treats residual tumor with radiation and chemotherapy, 
but poor patient survival highlights the challenges of tumor cell invasion for GBM 
therapy.   
Although GBM patient survival is not favorable, clinical-pathologic and molecular 
approaches suggest there are several forms of disease, and these affect patient outcome.  
Clinical-pathologic prognostic factors indicate that GBM behavior depends on patient age 
at diagnosis and performance status, in addition to grade (Scott, Scarantino et al. 1998, Li, 
Wang et al. 2011).  We recently developed a 9-gene molecular indicator of survival that is 
independent of patient age and tumor grade for patients treated with surgery, radiotherapy, 
and the alkylating agent temozolamide (Colman, Zhang et al. 2010).  One of the mRNA 
indicators, aquaporin 1 (AQP1), is a major contributor to this signature of GBM gene 
expression marking poor survival (Phillips, Kharbanda et al. 2006).  The work we report 
here investigates whether a biologic function of AQP1 underlies its relationship to 
survival, and determines whether its expression marks prognosis.  
Aquaporins quickly conduct water across membranes and prevent movement of 
various ions and other solutes (Gonen and Walz 2006). There are 14 known aquaporins in 
humans (Verkman 2005, Papadopoulos and Verkman 2013).  AQP1, 4, and 9 are found in 
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the central nervous system. AQP1 is expressed in cerebrospinal fluid-producing cells 
lining the ventricles, and highly expressed in migrating reactive astrocytes.  AQP4 is 
expressed in endothelial cells and astrocytes throughout the brain. AQP9 is found in the 
retina. 
Aqp1 is a 28 KDa cell membrane channel protein that allows rapid water 
movement in response to osmotic gradients. It is a 28KDa member of a large protein 
family (MIP – major intrinsic proteins) that forms pores in cell membranes.  Aqp1 
functions in water movement across membrane barriers in kidney, brain, eye, erythrocytes, 
GI tract, sweat glands, and vascular endothelia (Agre, King et al. 2002, Saadoun, 
Papadopoulos et al. 2002, McCoy and Sontheimer 2007, Hara-Chikuma and Verkman 
2008, Papadopoulos, Saadoun et al. 2008).  Expression in the central nervous system is 
typically limited to cells lining the ventricles, and extraventricular expression typically 
relates to pathological processes (Papadopoulos and Verkman 2013).  
Oncology literature suggests aqp1 is related to the malignant phenotype. Recent 
work indicates AQP1 is a prognostic indicator for clear-cell renal cell carcinoma(Huang, 
Murakami et al. 2009), and  neoplastic cells of several cancers, including GBM, highly 
express AQP1 RNA (Markert, Fuller et al. 2001, Saadoun, Papadopoulos et al. 2002, 
Hoque, Soria et al. 2006). One report indicates that aqp1 overexpression allows anchorage 
independent growth in NIH 3T3 cells (Hoque, Liu et al. 2000), and others suggest it 
enhances migration and localizes to cell processes associated with movement (Nagashima, 
Fujimoto et al. 2006, Verkman, Hara-Chikuma et al. 2008). Sontheimer et. al. showed that 
reactive astrocytes responding to brain injury express AQP1(McCoy and Sontheimer 
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2010), and that protein kinase C regulates aqp4 water permeability, which is rate limiting 
for glioma invasion(McCoy, Haas et al. 2010).   
We hypothesized both aquaporin 1 protein (aqp and mRNA  (AQP1) are 
prognostic markers for GBM patients based on AQP1’s presence in a survival-associated 
mesenchymal gene signature (Phillips, Kharbanda et al. 2006, Huang, Murakami et al. 
2009)and in a multi-gene predictor of survival (Colman, Zhang et al. 2010).  This 
manuscript builds on existing AQP1 mRNA microarray data by validating both protein 
and mRNA as prognostic in formalin-fixed, paraffin-embedded (FFPE) tissue sections of 
human tumors, and by suggesting that their relationship to invasion and motility underlies 
aquaporin1’s negative impact on glioma patient survival.   
 
Materials and Methods 
Human Patient selection 
We collected clinical data on patients with primary WHO grade IV GBM resected 
at the University of Texas M. D. Anderson Cancer Center from 1993 to 2005.  Accessible 
electronic and/or written clinical records, and formalin fixed, paraffin embedded (FFPE) 
tumor tissue were other selection criteria.  We excluded recurrent tumors.  We (K.D.A.) 
re-reviewed the histopathologic diagnosis of all tumors to confirm grading and evaluate 
tissue suitability for immunohistochemical (IHC) staining.  We collected patient clinical 
data, including age at diagnosis, date of surgery, date of last follow-up/death, vital status, 
and date of radiographic progression. The University of Texas M. D. Anderson Cancer 
Center Institutional Review Board approved all clinical studies. 
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Human Immunohistochemistry 
We carried out IHC staining of FFPE tissue with anti-human Aquaporin 1, clone 
1/22 mouse monoclonal antibody (Abcam,Cambridge, MA).  We incubated tissue in 
primary antibody at 4°C overnight at 1:7500 dilution.  Two independent reviewers scored 
IHC blinded to clinical data with a 3-tier system: high, strongly positive in the majority of 
tumor cells in at least 1 medium power (100 X) microscopic field; intermediate, 
weak/patchy staining in tumor cells; negative, no staining. We repeated the assay and 
reached consensus for cases with scoring discrepancy. We re-coded cases scored as 
intermediate and high as "positive" for multivariate analysis because univariate analysis 
did not distinguish between intermediate and high staining patient outcomes.  
 
Real-time, reverse transcription polymerase chain reaction (qRT-PCR) 
A neuropathologist (K.D.A.) selected FFPE tumor tissue for qRT-PCR by macro-
dissection based on representative hematoxylin and eosin stained sections.  We isolated 
total RNA with the MasterPure Complete RNA Purification kit (Epicentre 
Biotechnologies, Madison, WI) according to the manufacturer's instructions for paraffin-
embedded tissue. We reverse transcribed 10 µg of total RNA with random hexamers using 
TaqMan Reverse Transcription reagents (Applied Biosystems, Foster City, CA).  We 
performed and reported qRT-PCR results as previously described (Colman, Zhang et al. 
2010). 
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Statistical Analysis of GBM Cases 
The primary clinical endpoints for analysis were overall survival, progression-free 
survival, and response to radiotherapy.  We measured follow-up intervals from date of 
surgical resection to date of death or last contact.  We defined time to progression from 
the date of surgery to the date of tumor recurrence or growth as first documented by MRI. 
We used the method of Kaplan and Meier (Kaplan and Meier 1958) for survival analysis 
and made comparisons using the logrank test.  We determined univariate associations by 
2 test or, when appropriate, the Fisher exact test (Fisher 1922) for categorical variables 
and the Wilcoxon rank sum test (Wilcoxon 1945) or Student t-test, when appropriate, for 
associations with continuous variables.  We carried out multivariate analysis using the 
Cox proportional hazards model (Cox 1972) for survival or Spearman's rank sum test 
(Spearman 1904).  We determined the AQP1 qRT-PCR threshold best able to partition 
patients by vital status into high and low AQP1 expression by recursive partitioning.  
Analysis was in JMP 6.0.3 for Macintosh (SAS Institute, Cary, NC).  
 
AQP1 U251 Glioma Model.   
 We cloned human AQP1 cDNA and red fluorescent protein (RFP) into mammalian 
retroviral expression vector pLXSN (Clonetech, Mountain View, CA).  We generated and 
packaged pLXSN-AQP1, pLXSN-RFP, and pLXSN-EV (empty vector) virus with 
Phoenix A cells (American Type Culture Collection, Manassas, VA).  We infected U251 
glioma cells (American Type Culture Collection) and selected with appropriate antibiotics 
and by fluorescence activated cell sorting for RFP to generate stable nonclonal cell lines: 
U251 parental: U251 cells infected with pLSXN-RFP.  U251-AQP1:  U251 cells infected 
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with pLSXN-RFP and pLXSN-AQP1.  U251-EV: U251 infected with pLSXN-RFP and 
pLXSN.  We incubated all lines in Dulbecco’s Minimal Essential Medium (DMEM) with 
pyruvate, supplemented with 10% FBS, 1% non essential amino acids, and 1% L-
glutamine (all from Invitrogen, Grand Island, NY), at 37
0
C at 100% relative humidity 
(Jung, Kim et al.) under 5%CO2.  In some experiments, we treated the cultures overnight 
with tetraethylammonium chloride (TEA, TOCRIS, Ellisville, MO ). 
 
Immunocytochemistry on Cell Lines 
 We grew U251 derivative lines to 80% confluence on laminin coated coverslips, 
fixed with 4% paraformaldehyde for 10 min at room temperature, and washed 3X with 
phosphate buffered saline (PBS).  We permeabilized with 0.2% Triton X-100/PBS 
(Invitrogen, Grand Island, NY), blocked with 3% horse serum/PBS for 1hr at room 
temperature, and incubated at 4°C overnight with rabbit primary polyclonal antibody to 
aqp1 (Millipore, Billerica, MA) diluted 1:1000 in PBS.  Following three PBS washes, we 
incubated with secondary Fluorescein-5-Isothiocyanate (FITC) Donkey anti rabbit 
antibody (Millipore) diluted 1:500 with PBS on the coverslips for 2hr at room 
temperature. After washing 3X with PBS, we mounted the coverslips on slides with 4’, 6-
diamidino-2-phenylindole (DAPI)/Prolong Gold  (Invitrogen, Grand Island, NY), and 
imaged with a 63X/1.4NA oil immersion objective on a Zeiss 710 confocal microscope. 
We visualized the FITC by exciting with 488nm diode laser and collecting 505-525nm 
emission. We visualized DAPI by exciting with a 405nm diode laser and collecting 
emission at 450-475nm. Supplemental Figure 5 indicates Aqp1 localizes to apparent 
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lamellipodia of U251-AQP1.  This confirms previous literature (Papadopoulos, Saadoun 
et al. 2008), and suggests normal physiological localization of aqp1 in U251-AQP1 cells.   
 
Immunofluorescent Confocal Microscopy of Rat Brain Tumor Slices 
 We permeablized Serial 40um brain sections with PBS containing 0.3% triton, 
blocked with CAS block (Invitrogen), and incubated overnight in anti-aqp1 primary 
antibody (Millipore). The next day, we rinsed and incubated sections with Alexa488 anti-
rabbit secondary and DAPI (invitrogen). Following immunofluorescent labeling, we 
mounted sections on slides with Vectashield (Vector labs) and coverslipped with No:1.5 
glass.  
We imaged slides on a Zeiss LSM710 laser scanning confocal microscrope using a 
405nm laser to excite Dapi and a 488nm laser to excite Alexa488. Lasers were raster 
scanned sequentially to minimize overlap between emission spectra. We tiled low 
magnification images with a 10x/0.3NA air objective with the confocal aperature set to 
collect fluorescence from a 30um thick focal plane. For other magnifications, we set the 
confocal aperature to one Airy unit to minimize photon collection outside the focal plane. 
We acquired 20x images with a 20x/0.8NA objective, and 63x images with a 63x/1.4NA 
objective. We used NIH Image J linear functions for all image processing.  
Ki67 Cell Proliferation Assay 
We immunostained serial 4um paraffin-embedded sections from AQP1 overexpressing 
(n=5) and Control (n=5) xenograft tumors for Ki67 (MIB-1) and lightly counterstained 
with hematoxylin.  A neuropathologist (JE) calculated the MIB-1 labeling indices. 
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Cell Counting Proliferation Assay 
We plated 
 
10
5 
cells into 6 well plates (VWR, Radnor, PA) harvested in triplicate 
every day for 8 days and counted with a Z2
TM 
Coulter Counter (Beckman Coulter, Inc., 
Hialeah, FL.).  
 
Cell Survival Assay 
We plated 50-100 single cells/well of a 6 well plate, incubated for 10-20 days, and 
counted colonies in triplicate wells after staining with methylene blue. We define a colony 
as an aggregate of at least 50 cells (Franken, Rodermond et al. 2006).  
 
Wound closure assay.   
We plated ~10
5 
cells in 6 well plates, incubated to 100% confluence in 2-3 days, 
cleared a standard area with a pipette tip, and measured the gap with a Zeiss Axiovert 200 
inverted microscope using the Zeiss software line tool to define upper and lower 
boundaries. We typically measured 5 random sites/time point/cell type, and calculated 
means, standard deviation, and % gap closure based on differences between time of 
observation and time at start.  We obtained similar wound closure results using cell 
proliferation inhibitor hydroxyurea (5mM) (Sigma, St. Louis, MO), previously described 
as an inhibitor of cell proliferation (Jung, Kim et al. 2002).  
 
Water flux assay 
We plated five thousand U251-AQP1 cells into each well of a 96 well plate. After 
two hours, we reduced the volume of each well to 30ul and transferred the plate to the 
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stage of a DIC-capable Zeiss 710 LSM equipped with a transmitted light PMT.  While 
imaging at 2hz, we added 200ul of hypotonic (150mOsm) artificial cerebrospinal fluid 
(aCSF) to each well at ~130ul/second (Normotonic aCSF: 126 mM NaCl, 26 mM 
NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM CaCl2 and 10 mM 
glucose, pH 7.4).  We measured changes in cell cross-sectional area over time with image 
J software to estimate rate of cell swelling after hypotonic shock. We used a one-way 
ANOVA followed by a Fisher’s LSD multiple comparisons test to detect differences in 
cell cross sectional area among doses TEA.   
 
Boyden Chamber Migration Assay 
We starved cell suspensions of 0.5-1 x 10
6 
 cells/ml in serum free media 
overnight, added 300µl to the upper well of a Boyden Chamber (McCoy and Sontheimer 
2007) with CytoSelect Cell Migration 8µm pore size polycarbonate membrane inserts 
(Cell Biolabs, San Diego, CA)  and 500µl of media containing 10% fetal bovine serum to 
the lower wells.  We incubated 5hr at 37°C, 5% C02, aspirated the media inside the insert, 
transferred the insert to a clean well and quantitated migratory cells at the bottom of the 
insert with CyQuant® GR Dye (Jones, Gray et al. 2001) Kit (Invitrogen, Grand Island, 
NY) by detaching the cells, incubating in dye and reading on a fluorescent plate reader 
(Beckman Coulter, Brea, CA) at 520nm. 
 
Matrigel Invasion 
We cultured cells on glass-bottomed 35mm culture dishes with #1.5 optical glass 
coated with poly L Lysine (MatTek, Ashland, MA), aspirated media following adhesion, 
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covered cells with 100ul of matrigel (BD Bioscience, San Diego, CA), and incubated 15-
20min at 37°C to solidify. We replaced media above the matrigel, and incubated 36 hrs at 
37°C, 95% RH, 5% C02. We measured invasion with a Zeiss 710 inverted confocal 
microscope using Zeiss Zen software in z stack mode taking six readings on x/z and y/z 
line scans at 3 locations per dish. 
 
Murine Brain Slice Invasion 
All animal experiments reported in this manuscript were performed in accordance 
with the guidelines and regulations set forth by the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals and were approved by the Institutional Animal 
Care and Use Committee of the Barrow Neurological Institute of St. Joseph’s Hospital 
and Medical Center, Phoenix, Arizona.   
We decapitated a deeply anesthetized rat using 0.1-0.2 ml/250 g of 75.8mg/ml 
Ketamine and 4.8mg/ml of Xylazine, excised the brain, and placed it in cold sterile PBS.  
We cut a 4-5mm slice with a 1mm metal template, attached it to a platen in a Vibratome 
1500 (Vibratome, St. Louis, MO), cut 300µm coronal slices, floated each in a chamber 
slide in slice medium (DMEM, 10% FBS, 1% NEAA, 1% L-gluNH2, 1X 
Penicillin/streptomycin (Invitrogen, Grand Island, NY), and finally removed the medium, 
leaving a flat, centrally located slice. We injected approximately 1 x 10
5
 cells in 1µl on 
the caudate/putamen of the slice, adhered by incubating 1hr at 37°C, 95% RH, 5% C02, 
and incubated the preparation in slice medium.  We measured invasion with a Zeiss 710 
confocal microscope using Zeiss Zen software in z stack mode using six readings on x/z 
and y/z line scans at 3 locations per slice.  
  25 
 
Human Xenograft in Nude Rat 
Twenty-six male Crl:NIH-Foxn1
rnu
 rats (5 weeks age) from The Charles River 
Laboratories International, Inc. (Wilmington, MA) were anesthetized by intramuscular 
injection of of 10 mg/kg xylazine and 80 mg/kg ketamine (Wyeth, Madison, NJ) and 
placed in a rodent stereotactic headframe (Model 900, David Kopf Instruments, Tujunga, 
CA). A 10-mm incision was made to expose bregma. A bur hole was made 3.5 mm 
lateral to bregma. U251 (n=13 rats) or U251-AQP1 cells (n=13 rats) were infused at a 
depth of 4.5 mm below the surface of the brain after the syringe (Hamilton) was 
advanced 5.0 mm to create a 0.5-mm pocket. The cell suspension was infused using a 
UMP3-1 UltraMicroPump microinjector (WPI, Sarasota, FL) set to a volume of 10 µL 
with an infusion rate of 3.00 µL/minute. The needle was withdrawn 2 minutes after the 
injection to minimize backflow of the cell suspension. The bur hole was covered with 
bone wax, the skin incision was sutured, and the rats were allowed to recover. Rodents 
were monitored daily for dietary and behavioral changes, and were euthanized at first 
sign of morbidity.  
 
Results 
Aquaporin1 protein predicts poor GBM patient survival  
 
We evaluated 186 GBMs for aqp1 expression and correlated to patient outcome. 
Table 1 indicates patient characteristics. Progression-free survival. At a median follow-
up of 57 weeks, aqp1 was prognostic for progression-free survival (Figure 1A). The 
median actuarial time to progression was 36 weeks in the low expressing group compared 
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to 16 weeks in the high-expressing groups. The 6-month PFS was 18% vs. 37% in the 
low -expressing groups. Overall survival.  The median overall survival in the aqp1 high-
expressing group was 50 wks vs. 97 wks in the low-expressing group (p<0.0001, log-
rank test) (Figure 1B).  Recursive, split-sample validation achieved significance in all 
iterations by univariate analysis. Patients with high aqp1 expression had a nearly two fold 
increased risk of death compared to those with low expression. Multivariate analysis 
including age and extent of surgical resection demonstrated aqp1 was an independent 
prognostic factor (Table 2).  
 
AQP1 mRNA levels predict patient survival 
 We reverse transcribed total RNA derived from 67 formalin-fixed paraffin 
embedded (FFPE) GBM with sufficient available tissue and quantitated  AQP1 cDNA via 
qRT-PCR to support our IHC data. Tumors from patients with < 2yr survival had 2.9-fold 
higher median expression than tumors from patients with > 2yr survival (p=0.0069, 
Wilcoxon rank sum test) (Figure 1C).   Two yr survival for high vs. low tumor AQP1 
expression was 67% vs. 29%, consistent with IHC data (p=0.0001, log-rank test) (Figure 
1D) 
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Figure 1: Aquaporin-1 expression is prognostic in GBM.  (A) Progression-free survival.  
Kaplan-Meier curves demonstrate progression-free survival (PFS) probability for 186 
GBM patients as a function of aqp1 staining by IHC. The data show that high aqp1 
expression (red) is associated with poor PFS for patients with GBM. Kaplan-Meier curves 
demonstrate better PFS among patients with low aqp1 expression by IHC.  (B) Overall 
survival.  Low aquaporin-1 expression (blue) associated with improved overall survival.  
(C) qRT-PCR AQP1 on 71 FFPE GBM tumors. Values represent fold change (2
-ΔΔCt
) 
normalized to the tumor with lowest expression among all cases. Significantly higher 
RNA levels in tumors from typical GBM survivors (TS, <2yrs) compared to long-term 
survivors (LTS, >/= 2yrs) (Wilcoxon rank sum test).  (D) Recursive partitioning identified 
a cut-off for AQP1 expression that best separates survivors from deceased. Stratification 
(“low” <24.7 fold (blue); “high” >/= 24.7 fold (red)) correlated with OS.  
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Aqp1 overexpression stimulates glioma cell movement.   
In vitro wound closure (Figure 2A- 2C) and migration (Figure 2D) assays indicate 
direct correlation between AQP1 expression and glioma movement in the absence of host 
tissue.  At two days, wound closure rate was ~3 fold and migration rate ~4 fold faster in 
aqp1 overexpressors. 
Experiments in murine brain slices confirm increased invasion of U251-AQP1 
overexpressors over U251-EV empty vector controls (Figure 2E).  At day 2, controls 
invade approximately 35 um, but U251-AQP1 overexpressors invade approximately 51 
um.   Similarly, cultures under matrigel indicate that AQP1 overexpressers bleb more and 
migrate faster than U251-EV empty vector controls at 36 hr (29.9 +/- 12.0um vs. 19.27+/-
9.5um; p=0.02).  (Supplemental Figure 1).   
Experiments with the putative inhibitor of Aqp1-mediated water diffusion, TEA 
(Figure 2E) suggest motility is related to aqp1 function.  The dose response curve for 
U251-AQP1 indicates 100 µM TEA limits wound closure to 10%.   Literature (Brooks, 
Regan et al. 2000) suggests that tetraethylammonium chloride (TEA) blocks aqp1 
channels at this concentration. Water flux studies indicate a dose dependent relationship 
between TEA and Aqp1-mediated water transport in our cells, and confirms that our TEA 
concentrations inhibit water transport (Supplemental Figure 2). The motility increase in 
empty vector controls at 0.03 mM TEA and in U251-AQP1 at higher TEA concentrations 
suggest that TEA action – and U251 motility - are not simple functions of aqp1 water 
transport activity.  
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Figure 2: AQP1 overexpression enhances U251 motility.  (A) Wound closure of U251-
EV with empty vector expression at 2 days (B) Wound closure of U251 with AQP1 
overexpression at 2 days; note greater wound closure compared to U251-EV.  (C) U251-
AQP1 close wounds faster than U251-EV and parental controls 2 days after scratch; p= 
0.0008.  (D) U251-AQP1 overexpression increases migratory activity in a Boyden 
chamber assay. Parental U251 and U251-EV are negative controls. Relative fluorescence 
units are proportional to the number of cells moving across a membrane in the chamber.  
Stable AQP1 overexpressors (AQP1-U251) migrated more quickly than either control 
(p= 0.037). ( (E) U251-AQP1 is more invasive than U251-EV in Thy1-YFP mouse brain 
slice. (Day 2 p-value is 9.9E-09) (F) Putative Aqp1 inhibitor tetraethyl ammonium 
chloride (TEA) inhibits wound closure. TEA inhibits wound closure of AQP1-U251 but 
not controls in a dose dependent fashion. The error bars reflect +/- 1SD.  Scale bars equal 
200um.  
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Supplemental Figure 1: U251-AQP1 Migrates faster in Matrigel than control, U251-EV 
at 24 hr.   Confocal images of cells growing into matrigel layered onto cultured cell 
monolayer.  Z Axis indicates matrigel depth.  Note blebbing in U251-AQP1 (AQP1) are 
absent in U251-EV (Control).  
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Supplemental 2: TEA attenuates AQP1 mediated water transport. After 150mOSM 
hypoosmolar exposure, U251-aqp1 cells’ cross-sectional area increased at a rate at least 
four-fold greater than control cells (pLXSN) and TEA treated cells. Cross sectional area 
of U251-aqp1 cells dosed with 0.03mM TEA increased significantly faster than higher 
TEA doses, but were significantly slower than U251-aqp1cells not treated with TEA. 
This suggests a dose response relationship between apparent water transport as measured 
by cell swelling and concentration of the putative channel blocker TEA.   
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Control experiments suggest that aquaporin overexpression does not affect 
proliferation or cell survival in U251-AQP1 overexpressors and U251-EV controls in 
culture.  Our xenograft data confirm this: the MIB-1 labeling index in the most 
proliferative areas was 49.5% for control tumors and 51% for AQP1 over-expressing 
tumors (Supplemental Fig 3). The results indicate equivalent cell proliferation in U251-
AQP1 overexpressors and U251-EV controls. 
Aqp1 immunohistochemistry and confocal fluorescence imaging in rodent 
xenografts confirm that U251-AQP1 tumors are more invasive than U251-EV controls 
(Figure 3). The AQP1 cells created a tumor edge with cell clusters/cords that appeared 
infiltrative (Fig 3A-3E), whereas the controls produced a circumscribed tumor with a 
more solid edge (Fig 3F-J).  Furthermore, we identified U251-AQP1 cells migrating in 
white matter tracts and in corpus callosum, where Aqp1 expression was directed toward 
the contralateral hemisphere (Supplemental Fig 4).  Controls did not exhibit this invasive 
behavior.  However, both Aqp1 overexpressors and empty vector controls had 
pleomorphic nuclei. 
 
Glioblastoma AQP1 overexpression decreases survival in rodent xenografts 
We produced rodent orthotopic xenografts from human control U251 and U251-
AQP1 glioma cells (n= 13 rodents per group). Kaplan-Meier curve and log rank test show 
median survival for rodents implanted with control U251 glioma cells is 36 days 
compared to 29 days for U251-AQP1 rodents; p=0.0002 (Figure 4).  
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Supplemental figure 4: U251-AQP1 cells in white matter tract orient Aqp1 expression 
towards contralateral hemisphere. Confocal image of immunostained brain section from 
rodent xenograft implanted with U251-AQP1. Section stained for Aqp1 (green) and cell 
nuclei (blue). (A) Low magnification of tumor margin near the corpus callosum. Dashed 
line indicates location of brain hemispheric separation. (B) Inset from A with AQP1-
expressing cell in the corpus callosum. Note AQP1 expression oriented away from tumor 
and toward contralateral hemisphere. Scale bar equals 50um  
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Supplemental Figure 3: AQP1 expression does not alter in vivo tumor proliferation. (A-
B)Sections from rodent xenografts immunostained with the proliferative marker Ki67 and 
counterstained with hematoxylin.  (C)  U251-pLXSN tumors and U251-AQP1 tumors do 
not have significantly different Ki67 proliferative indices (p=0.42).      
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Figure 3: Aquaporin-1 expression enhances infiltration at the tumor margin. Confocal 
fluorescence images of Aqp1- overexpressing (A-E)  and control (F-J) xenograft tumors 
stained for Aqp1 (green). DAPI counterstain (red) indicates cell nuclei. (A) Aqp1 staining 
shows expression maintained in vivo. (B) DAPI staining of Aqp1-expressing brain 
section reveals hypercellular tumor.(C) DAPI and Aqp1 staining merged. Note overlap 
between Aqp1 and tumor.  (D) DAPI staining at inset in Fig 3C; DAPI stained nuclei of 
infiltrative U251 cell clusters/cords at the tumor margin (arrows). (E) Aqp1 expression in 
infiltrative cell clusters/cords in Fig 3D (F) Minimal aqp1 staining in control tumor. (G) 
DAPI staining of brain section reveals hypercellular control tumor. (H) Merged image. (I) 
Inset from Fig 3H; note well-defined tumor border with solid tumor structure (arrows). 
(J)  Merged image from fig 3H shows minimal Aqp1 staining. Scale bars equal 500um (C 
& H) and 20um (E & J).  
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Figure 4: Aquaporin-1 overexpression decreases survival of rodent xenografts. Kaplan-
Meier comparison of rodents intracranially implanted with human U251-AQP1 glioma 
cells to rodents implanted with control U251 glioma cells. Mean survival of U251-AQP1  
xenografts is 29 days versus 36 days for control xenografts; p = 0.0002.  
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Supplemental 5: Aqp1 Immunocytochemistry.  We grew RFP-expressing U251-AQP1 
cells on coverslips to ~70% confluence. Polyclonal antibody to Aqp1 and FITC conjugate 
secondary antibody confirm membrane bound Aqp1 (green) in edge extensions (1). Scale 
bar equals 5um.   
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Discussion 
Our data indicate aquaporin 1 protein (aqp1) and message (AQP1) gauge GBM 
patient outcome, play a critical role in invasion, but do not affect cell proliferation or cell 
survival.  The data suggest aqp1’s clinical effects are related to its effects on motility, and 
not on cell growth or survival.  
Median overall and progression free survival doubled when GBM had low aqp1, 
median survival quadrupled when tumor had low AQP1, and tumors from long term 
survivors (> 2 yr OS) expressed about 50% less AQP1 than tumors from typical 
survivors.  This prognostic power is independent of age, performance status, or extent of 
resection (Fig 1, Table 2). The results mirror previous descriptions of a mesenchymal 
GBM group associated with poor survival (Phillips, Kharbanda et al. 2006) and a nine 
gene predictor of survival after standard therapy (Colman, Zhang et al. 2010). AQP1 was 
the leading prognostic indicator in the nine gene predictor series. 
We show in Supplemental Figure 5 that aqp1 localizes to edge processes of the 
cell called lamellipodia (Saadoun, Papadopoulos et al. 2005). Lamellipodia are sheetlike 
extensions of cytoplasm forming transient adhesion to the cell substrate enabling 
movement.  The data indicate that aqp1 protein is closely associated with cell movement. 
Our data demonstrate that AQP1 expression correlates directly with cell migration 
and invasion as shown by wound closure, Boyden Chamber, brain slice, and matrigel 
assays (Figure 2 and Supplemental Figure 1).  The wound closure rate tripled for U251-
AQP1 compared to U251-EV controls and migration rate in a Boyden chamber 
quadrupled for U251-AQP1 compared to U251-EV control.  The murine brain slice assay 
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indicates much greater invasion for U251-AQP1 than U251EV.  The matrigel invasion 
data support the wound and Boyden chamber data.  Invasion of U251-AQP1 is 2-3X the 
rate of U251-EV in matrigel after 24hr incubation. The results indicate that aqp1 protein 
is closely associated with cell movement.   
Literature supports our wound and Boyden Chamber assay results. Stable 
transfection of non-endothelial cells with AQP1 accelerated cell migration(Saadoun, 
Papadopoulos et al. 2005) and aqp1-deficient kidney epithelial cells slowed migration 
measured by in vivo  wound healing, and by Boyden chamber assay (Hara-Chikuma and 
Verkman 2006). AQP1 and AQP5 levels also correlated with invasion in human corneal 
epithelial cells (HCEC) and cell lines (CEP117) (Shankardas, Patil et al. 2010).    
Verkman hypothesizes (Verkman 2005) that aqp1 expression on lamellipodia of 
migrating cells allows alterations in osmolality following actin depolymerization and ion 
influx to  drive water flux, increasing local hydrostatic pressure and regulating membrane 
protrusion. Data suggest that aqp1 localizes to lamellipodia and allows quick changes in 
lamellipodial volume (Verkman, Hara-Chikuma et al. 2008). The hypothesis predicts 
greater water diffusion mediated by aqp1 results in faster cell movement. Our IHC data 
support this hypothesis by localizing aqp1 to the lamellipodia involved in migration.  
This typical aqp1 pattern of distribution also suggests that overexpressed aqp1 in our 
model emulates natural protein distribution after translation, and suggests that 
relationships between aqp1 and motility in our model represent physiologic aqp1 
function.  
Central nervous system AQP1 expression is typically limited to ependymal cells 
of the choroid plexus (Oshio, Watanabe et al. 2005, Papadopoulos and Verkman 2013).  
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Therefore, AQP1 overexpression within glioma cells suggests tumor cell genetic 
instability and/or presence of a different cell type.     
 Our nude rat xenograft model demonstrates aggressive behavior of U251-AQP1 
cells.   Figure 3 and supplemental 4 indicate an infiltrative growth pattern at the tumor 
margin compared to the well-delineated tumor in U251-EV controls. Figure 4 shows the 
effect of GBM AQP1 overexpression on rodent survival. The results suggest the 
relationship between poor survival and aqp1 expression in human disease results from 
aqp1’s effects on tumor motility. Histologically, nuclei were equally pleomorphic in 
control and AQP1 overexpressors and the proliferative index was similar between both 
groups (Supplemental Figure 3). Our data suggest aqp1 expression does not affect cell 
proliferation or colony formation, consistent with other reports (Saadoun, Papadopoulos 
et al. 2005, Hara-Chikuma and Verkman 2006) . 
Water penetration across tissue compartments is an important function of aqp1.  
The relationship between motility and TEA treatment (Figure 2E) suggests aqp1-
mediated motility is not entirely regulated by water movement, and confirms that TEA 
concentrations we use for the experiment reported in fig 2E inhibit water transport in our 
system. The motility increase in empty vector controls at 0.03 mM TEA and in U251-
AQP1 at higher TEA concentrations suggest that TEA action – and U251 motility - are 
not simple functions of aqp1 water transport activity. TEA’s ability to inhibit aqp1-
mediated water permeation was originally established and then validated by 
mutagenizing loop E of aqp1(Jung, Kim et al. 2002).  Our data indicate that TEA inhibits 
Aqp1 mediated water transport and wound closure in a dose dependent manner – 100 uM 
is the optimal inhibitory concentration for wound closure.  The small motility increases in 
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U251-AQP1 overexpressors at higher TEA concentrations suggest TEA also affects other 
processes associated with motility.  Its ability to increase motility in control U251 cells 
strengthen this likelihood.  In our experiments, controlling for TEA’s nonspecific effects 
on motility strengthen aqp1’s relationship to motility. One well-known activity of TEA is 
to inhibit K+ channel function (Post, Hume et al. 1992); perhaps this or other effects of 
TEA are a basis for the  behavior we document in Figure 2E.  Literature suggests TEA 
inhibition of Cl- and K+ channels result in inhibition of human malignant glioma cell 
invasion(Soroceanu, Manning et al. 1999) although increases in the motility of control 
cells (Figure 3E) suggest this is not the case in our system.  
 
Conclusion 
Aqp1 is an independent prognostic factor in GBM patients.  Our studies of aqp1 
overexpression suggest its effects on cell migration form the basis of this protein’s ability 
to affect patient outcome.  These data suggest aqp1 is a candidate for therapeutic 
intervention. 
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Table 1. Characteristics of patients examined for aqp1 expression 
 
 Value N (%) 
Total patients  187 (100) 
Median age, years 59   
Age range 19-84    
 Number <50y   47 (25) 
 Number ≥50y   140 (75) 
Median follow-up, weeks 55   
 Follow-up range, weeks 1-394   
Median survival (weeks)    
 Overall 58   
 Progression-free 26   
Vital Status    
 Alive  36 (19) 
 Deceased  151 (81) 
Karnofsky Performance Status    
 <70  5 (3) 
 70 – 80  82 (44) 
 90 – 100  100 (53) 
RTOG RPA Class (Scott, 
Scarantino et al. 1998) 
   
 III  29 (16) 
 IV  134  (73) 
 V+VI  21 (11) 
Surgical Resection    
 Gross-total  97 (52) 
 Subtotal  88 (47) 
 Biopsy only  2 (1) 
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Table 2: Aqp1 expression is an independent predictor of survival.  
 
Variable Hazard Ratio (95% CI) p-value 
Age (<50y vs. ≥ 50y) 2.3 (1.5 – 3.7) 0.0001 
KPS (<70 vs. 70-80) 1.1 (0.5 – 1.0) 0.0980 
 (70-80 vs ≥90) 1.4 (0.4 – 2.6)  
Surgical resection  
(GTR vs. STR/biopsy) 
1.2 (1.0 – 1.4) 0.0850 
Aquaporin-1  (high vs. low) 1.9 (1.3 – 2.9) 0.0001 
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     CHAPTER 2B 
AQUAPORIN-1 OVEREXPRESSION ENHANCES GLIOMA CELL MOTILITY 
INDEPENDENTLY OF WATER TRANSPORT 
Introduction 
New brain tumors arise in more than 40,000 Americans each year. They are the 
second most common cause of cancer death up to age 35, with a slight peak among 
children between 6 and 9 years old, but these tumors are most common among middle-
aged and older adults. About half of brain tumors are primary - i.e. their origin is 
intracranial; the remaining are metastatic. Clinical prognostic factors for primary brain 
tumors include tumor grade, patient age, performance status, and radiation response (DP 
Byar 1983, Mahaley, Mettlin et al. 1990, Daumas-Duport 1992, Barker, Prados et al. 
1996). Grade IV glioma (GBM) is the most common primary brain tumor. Standard 
GBM treatment is surgical resection followed by radiation and temozolomide (Hegi, 
Diserens et al. 2005). Aggressive resection improves survival (Sanai and Berger 2008). 
However, infiltrative cells remain following GBM resection leading to recurrence. 
We recently reported aquaporin-1 (aqp1) gene and protein as predictors of GBM 
infiltration and patient survival. A clinical nine gene predictive indicator of GBM 
survival suggests AQP1 is independently prognostic (Colman, Zhang et al.). AQP1 
expression is linked to increased motility in normal and neoplastic glial cells(McCoy and 
Sontheimer 2007). Our previous work shows that AQP1 promotes GBM migration and 
invasion. AQP1 is also linked to motility in neoplasms of the breast, CNS, and lung 
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(Verkman, Hara-Chikuma et al. 2008).  Thus, developing an aqp1-targeted GBM therapy 
may provide a versatile antineoplastic. However, the mechanistic role of aqp1-mediated 
motility is unknown.    
     We know of 16 aquaporin proteins (aqp) - water channels that facilitate 
transmembrane water movement. Some aquaporin genes - AQP-1, 3, 4, 5, and 9 - are 
implicated in cell motility (Loitto, Karlsson et al. 2009). Functional inhibitors of 
aquaporin water transport are nonspecific (TEA), and/or toxic (Hg). Thus, independent 
study of aqp1-mediated water transport on cell motility is not possible with current aqp1 
inhibitors.  
Non-water permeating aqp1 mutants allow specific study of aqp1’s water channel 
(Yool 2007). Aqp1’s 267 amino acid sequence consists of cytosolic loops B and D and 
extracellular loops A, C, and E. In aqp1’s tertiary structure, NPA motifs of loops B and E 
interact to form the water pore. Mutants alter the alignment of these motifs and restrict 
water transport. One well-characterized aqp1 mutant substitutes an asparagine for the 
glutamic acid at the 17 position of the protein (e17n). This mutant functionally inhibits 
water transport without altering other characteristics of the protein.  (Jung, Preston et al. 
1994).   
     Although specific inhibitors of aqp1-mediated water transport are under 
development (Antonio Frigeri 2007, Yool 2007), their antineoplastic activity has not been 
rigorously studied. This work investigates the relationship between aqp1 water transport 
and GBM invasion by studying the effects of e17n overexpression in human GBM cells. 
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We hypothesize glioma cells overexpressing e17n will have impaired motility compared 
to glioma cells overexpressing aqp1. 
 
Materials and Methods 
Cell lines  
 We cloned aquaporin-1 (AQP1) and mutant non-water permeating aquaporin-1 
(e17n) cDNA into mammalian retroviral vector pLXSN(clonetech), and generated viral 
particles with PhoenixA cells. We infected two human cell lines (Ln18,U251) with aqp1, 
e17n, and empty vector cDNA. Cells were selected with 1mg/ml of genticin (Gibco) for 
three weeks and tested for aqp1 and e17n expression by and immunofluorescence. Cells 
were maintained in standard DMEM culture media without antibiotic supplementation. 
 
Immunofluorescence   
 Cells were cultures on No. 1.5 coverslips and fixed with 4% paraformaldehyde 
then rinsed 3x10 min in PBS, permeabilized with 0.3% triton for 1 hour, and blocked for 
1 hour (Cas Block; Invitrogen). Samples were then incubated overnight in 0.1% aqp1 
primary antibody (Millipore), rinsed 3x15min with PBS, and incubated with Alexa488 
secondary antibody. Samples were incubated for 15 minutes in DAPI and placed on 
slides with #1.5 coverslips. 
 We imaged the fluorescently stained cells with a Zeiss710 laser scanning 
confocal microscope using zen software. DAPI was visualized with 405nm excitation and 
450nm emission, and Alexa488 with 488 excitation and 525nm emission. To minimize 
signal overlap between each fluorophore, we sequentially rastered each laser line during 
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excitation. We minimized collection of signal from outside the focal plane by setting the 
confocal aperature to one Airy unit.    
Cell Swelling Assay  
 We placed 1,000 cells into wells of a 96-well glass bottom plate (MatTek). Cell 
swelling was monitored during immediate 200mOSM hypotonic shock at 2hz using a 
Zeiss laser scanner confocal microscope (Zeiss LSM710/Live Duo) set for transmitted 
light microscopy. We quantified the rate of cell swelling by measuring cell cross 
sectional areas with NIH image J software.  
 
Wound Assay  
 We seeded 200,000 cells into each well of a six well plate. At 100% confluency, a 
line of cells was removed from each well with a p200 pipette tip. Five points per scratch 
were imaged with a Zeiss inverted phase contrast microscope equipped with a motorized 
stage and mark and find module. Identical regions were imaged every twelve hours for 36 
hours and data was analyzed by repeated measures ANOVA followed by Tukeys multiple 
comparisons test.  
 
Growth Assay  
 We conducted growth assays on U251 and Ln18 cell lines by seeding 35,000 cells 
into each well of a twelve well plate. We trypsinized and counted cells from 4 wells per 
cell type (control, e17n, and aqp1) with a coulter counter at days 1,3,5, and 9. Data was 
grouped by parental cell line and analyzed by ANOVA and Tukeys multiple comparisons 
tests. 
  51 
Rodent xenografts 
  All animal procedure were approved by ASU/BNI IACUC committees in 
agreement with NIH standards. Five-week-old male athymic rats were anesthetized with 
ketamine/xylazine/acepromazine and placed into a stereotaxic frame(Kopf). A 5mm 
midline incision was made superficial to bregma, and a small burr hole was created at 3.5 
lateral to bregma. We infused 1.0x10
6
 cells suspended in 10ul of serum free media 
4.5mm deep at 3ul/min (Quintessential Injector;Stoelting). Animals were administered 
Caprofen to minimize discomfort following surgery and monitored animals daily for 
morbidity. 
 
Histology 
  Rodent xenografts were deeply anesthetized and sacrificed by cardiac perfusion 
of PBS followed by fresh 4% paraformaldehyde (PFA). Brains were excised, fixed 
overnight in 4degree celsius PFA, and rinsed three times with PBS. Brains were 
embedded in paraffin, sectioned at 5um and stained with hematoxylin and eosin.  
 
Results 
 Immunofluorescence 
  To study targeted inhibition of aqp1 water transport, we acquired a mutant 
Aquaporin-1 (e17n) that has restricted water transport (Yool 2007). We infected two gbm 
cell lines (Ln18 and U251) with aqp1, e17n, and EV viral vectors. We used 
immunofluorescence to show aqp1 and e17n expression in transduced cells and 
negligible native aqp1 expression in controls (Figure1: A-F).  
1a 1b 
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Figure 1: Expression of aquaporin and e17n in two human glioma cell lines.  
Immunofluorescent images of U251 cells infected to overexpress AQP1 or e17n  (DP 
Byar). Dapi counterstain to visualize cell nuclei. (A,D) U251 and Ln18 cells transduced 
with AQP1 strongly express the protein in the cytoplasm and cell membrane. (B,E) Cells 
infected with e17n localize the protein to the plasma membrane and cytoplasm. Note 
greater cytoplasmic localization for the mutant aqp1 (C,F). Empty vector U251 and Ln18 
cells express minimal aqp1.  
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Water Flux Assay 
 We utilized a water flux assay to test the function of e17n. We monitored the 
percent change in cell cross-sectional area by time-lapse imaging after immediate 
exposure to hypotonic (200 mOsm) aCSF. We found cells expressing aqp1 increased in 
cross-sectional area at a greater rate than e17n or empty vector control cells which did not 
differ in rate of increase (p< 0.0001). This confirms aqp1 overexpression increases water 
flux whereas e17n expression does not increase water flux above rate of control cells 
(Figure 2). 
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Figure 2: Water flux assay AQP1 overexpressing glioma cells transport water at a greater 
rate than mutant and empty vector cells. (Verkman, Hara-Chikuma et al.) Cells prior to 
hypo-osmotic challenge. (D-F) Cells during 200mOsm challenge. Note multiple 
membrane blebs in AQP1 overexpressing cells. (Bar Graph) AQP1 overexpressing cells 
transport water at a greater rate than e17n and empty vector cells.  
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Cell Motility    
 We tested e17n-mediated motility with a wound assay. Two cell lines engineered 
to express aqp1, e17n, and empty vectors were cultured. A wound was made in each well 
once cells reached confluency. We found e17n and aqp1 overexpression both 
independently promote wound closure in GBM cells compared to control cells (p< 0.05) 
(Figure3: A-E)  
 
Cell Growth  
 We implanted a growth curve to determine effects of aqp1 and e17n on cell 
growth. We observed the greatest rate of cell growth occurred between days 3 and 5 for 
all cell groups. There was no difference between growth of control cells or e17n and aqp1 
overexpressing cells at any time point for Ln18 and U251 cell lines (p> 0.05)(Figure3: 
F&G) .   
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Figure 3: Cell Motility and Growth 
Aqp1 upregulates motility independently but does not alter cell proliferation.. (A-E) 
Wound closure assays. (Verkman, Hara-Chikuma et al.) Phase contrast images of (A) 
empty vector U251, (B) e17n-U251, and (C) AQP1-U251 after 36hours of wound. (D,E) 
Empty vector u251 show decreased wound closure at 36 hours compared to e17n and 
AQP1 expressing glioma cells. (F,G) Cell growth assays. (F)Ln18 and (G) U251 cells 
overexpressing AQP1 and e17n have similar growth to empty vector control cells. Scale 
bar equals 200um. 
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Rodent Xenografts  
 We intracranially injected male nude rats with 1.0x10
6 
newly developed U251 
cells expressing aqp1, e17n, and empty vectors. H & E staining of these xenografts 
contrasts normal tissue with lighter staining, and neoplastic tissue with dark staining. Our 
data suggest both aqp1 and e17n produce more infiltrative tumor margins than tumors not 
overexpressing these proteins. (Figure4: A-C).  
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Figure4: Mutant Xenograft Histology 
AQP1 enhances brain tumor infiltration and decreases rodent survival. (Verkman, Hara-
Chikuma et al.) H and E stained sections from rodent xenografts. (A) Empty vector 
control human glioma cell tumor border. Note well delineated tumor margin. (B) Aqp1- 
overexpressing tumor margin with infiltrative cells. (C) Mutant aquaporin tumor with 
infiltrative tumor margin. Scale bar equals 200um.  
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Discussion 
 Aquaporin-1 is upregulated in cancers of the breast, colon, and kidney (Otterbach, 
Callies et al. 2008, Huang, Murakami et al. 2009, Jiang 2009). Our previous work 
additionally showed AQP1 was overexpressed in glioblastoma (Oshio, Binder et al. 
2005). We found aqp1 to be predictive of GBM patient survival, with low aqp1 
expressors surviving 97 weeks, and high expressors surviving an average of 50 weeks. In 
GBM, aqp1 increases the infiltration of tumor cells without effecting their growth or 
proliferation. A similar hyper-motile phenotype is appreciated in other cancers that over-
express aqp1 (Hu and Verkman 2006, Jiang 2009). Current hypotheses attribute changes 
in motility to water transport (Papadopoulos, Saadoun et al. 2008). However, our findings 
suggest aqp1 harbors a water transport-independent function that accelerates cell motility. 
 Therapeutic targeting of AQP1 is hindered by the lack of aqp1-specific agents. To 
circumvent this, researchers have used non-specific water channel inhibitors such as 
mercury and tetraethylammonium (TEA). However, these inhibitors block additional 
channels (ie: TEA) and/or are toxic (ie:Hg) (Brooks, Regan et al. 2000, Farina, Rocha et 
al. 2011). Therefore, our findings that e17n and aqp1 similarly increase motility in glioma 
cells suggest pure inhibition of water transport will not necessarily inhibit aqp1-mediated 
motility. 
 Our observations suggest aqp1 up-regulates cell motility independently of water 
transport. Others have eluded to multiple functions for aqp1 (Monzani, Bazzotti et al. 
2009, Yool and Campbell 2012). In our studies, we developed glioma cells expressing a 
mutant aqp1 incapable of water transport (e17n). We verified the lack of water transport 
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for e17n with hypotonic cell-swelling assays and found e17n-expressing cells to transport 
water at a similar rate to empty vector control cells; a rate much less than cells expressing 
aqp1. Our in-vitro assays show that glioma cell lines over-expressing e17n have 
enhanced motility similar to cells over-expressing wild-type aqp1. 
 Our previous work with rodent xenografts showed that a typically non-invasive 
human glioma cell line could become more invasive after aqp1 overexpression. The 
infilitrative margins we observed in e17n- overexpressing tumors suggest this effect is 
independent of water transport. This is in contrast to control tumors that produce well-
demarcated tumor margins.  
 We recognize limitations in our work include the use of cell lines that do not fully 
recapitulate the human form of GBM. Future work exploring the effects of aqp1 and e17n 
expression in primary tumor cells and neurospheres may provide additional insight 
towards the mechanism(s) decreasing human survival.  However, our data suggest 
targeting aqp1 molecular regions outside the water channel may be required to control the 
malignancy of high grade tumors such as glioblastoma. 
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CHAPTER 3 
CONTRAST-FREE MICROSCOPIC ASSESSMENT OF GLIOBLASTOMA 
BIOSPECIMENS PRIOR TO BIOBANKING 
 Glioblastoma (World Health Organization grade 4 glioma; GBM) is the most 
common primary brain tumor with a 12-15 month median patient survival. Improving 
patient survival involves better understanding the biological mechanisms of GBM 
tumorgenesis and seeking targeted molecular therapies. Central to furthering these 
advances is the collection and storage of surgical biopsies (biobanking) for research. 
Unfortunately, due to the necrotic feature of GBM and our inability to assess tissue prior 
to biobanking, the majority of biobanked GBM samples lack appropriate cellularity to be 
utilized in research. This manuscript addresses an imaging modality (confocal reflectance 
microscopy; CRM) for safely screening GBM biopsies prior to biobanking to increase the 
quality of tissue provided for research and clinical trials. CRM is a light scattering 
imaging modality that can generate contrast from cells and tissue without exogenous 
contrast agents. Our data indicate that CRM can immediately identify cellularity of tissue 
biopsies from animal models of GBM. When screening fresh human biopsies, CRM can 
differentiate a cellular GBM biopsy from a necrotic biopsy. Compared to controls, CRM 
does not alter the DNA, RNA, or protein expression of sampled tissue. Our data illustrate 
CRM’s potential for rapidly and safely screening clinical biopsies prior to biobanking. 
This information can augment data gained from resected tissue for molecular and 
translational research, and for determining the eligibility of GBM patients for enrollment 
into clinical trials. Secondly, this method provides a digital histological record of a 
biopsy that can be stored along with a biobanked specimen. Our data show CRM to be a 
  64 
robust screening technique that can improve the quality of tissue biobanked for 
glioblastoma patients. 
 
Introduction 
 Each year, over 22,000 Americans are diagnosed with high-grade gliomas. More 
than half of these brain tumors are Glioblastoma (GBM), the most aggressive and 
essentially non-curable form of this disease (Dolecek, Propp et al. 2012). Standard 
treatment for newly diagnosed GBM is surgical resection followed by ionizing radiation 
and chemotherapy (Lefranc, Brotchi et al.) . However, current therapeutic approaches 
provide minimal survival benefit with median survival remaining formidably at 12 
months and two-year survival remaining less than 30%  (Stupp, Mason et al. 2005, 
Furnari, Fenton et al. 2007). 
  A key component to improving patient survival involves a better understanding 
of the biological mechanisms in tumor formation and seeking targeted molecular 
therapies (Mohyeldin and Chiocca 2012). With recent advances in medical genetics, 
computational biology, and biotechnology, novel molecular approaches such as immune, 
vaccine, and gene therapy are being extensively explored in treating brain tumors. Central 
to furthering these advances requires collecting surgical biopsies (biobanking) to study 
for gliomagenesis or to assess a patient’s eligibility for potential life-prolonging clinical 
trials.  Unfortunately, due to the necrotic feature of malignant gliomas and our inability to 
assess tissue prior to biobanking, the majority of biobanked GBM samples lack 
appropriate cellularity to be utilized in these two research arenas. A method for safely 
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screening tissue biopsies prior to biobanking is needed to increase the quality of tissue 
provided for research and clinical trials.  
Confocal reflectance microscopy (CRM) is an optical imaging modality that can 
rapidly assesses tissue without physical manipulation or application of exogenous 
contrast agents (Campo-Ruiz, Ochoa et al. 2002, Tilli, Cabrera et al. 2007). In CRM, a 
laser is raster-scanned across a specimen without generating a detectable stokes-shift. 
Photons from the laser are scattered back towards the objective and passed through a 
confocal aperature. This allows multiple optical sections to be collected from a sample 
without physical sectioning. When applied to thick tissue samples, CRM can identify 
individual cells and structural components within the tissue (Campo-Ruiz, Ochoa et al. 
2002). Compared to other optical sectioning techniques (ie: fluorescence confocal 
microscopy, structured illumination, non-linear microscopy), CRM introduces a fraction 
of energy into tissue samples. Thus, it is least likely to alter tissue characteristics by 
generation of free radicals or thermal energy. 
We hypothesized CRM would provide a safe and rapid means for screening GBM 
tissue appropriate for biobanking. In this study we first utilize CRM to assess tissue 
cellularity from rodent glioma models, then evaluate alterations to the molecular integrity 
of tissue imaged with CRM. Lastly, we test CRM on clinical samples with a pathology-
based CRM system. Our data illustrate CRM’s potential for screening clinical biopsies 
prior to biobanking. Though multidiscipline applications for intraoperative CRM exist, 
our immediate goal is to determine its efficacy as a robust screening technique that will 
improve the quality of tissues collected and biobanked for brain tumor patients. 
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Material and Methods 
Intracranial implantation  
Nude rats were acquired from Charles River Laboratories. Rats (n=5) were 
anesthetized by intramuscular injection of a mixture of 10 mg/kg xylazine and 80 mg/kg 
ketamine (Wyeth, Madison, NJ) and placed in a small animal stereotactic headframe 
(Model 900, David Kopf Instruments, Tujunga, CA). A 10-mm incision was made 
starting between the animal’s eyes to expose bregma. A bur hole was made 3.5 mm 
lateral to bregma. Human glioma cells (U251; ATCC) were infused at a depth of 4.5 mm 
below the surface of the brain after the syringe (Hamilton) was advanced 5.0 mm to 
create a 0.5-mm pocket. The cell suspension was infused using a UMP3-1 
UltraMicroPump microinjector (WPI, Sarasota, FL) set to a volume of 10 µL with an 
infusion rate of 3.00 µL/minute. The needle was withdrawn 2 minutes after the injection 
to minimize backflow of the cell suspension. The bur hole was covered with bone wax, 
the skin incision was sutured, and the rats were allowed to recover.  
 
Rodent tissue 
Twenty-eight days after implantation, rodent xenografts were deeply anesthetized 
using xylazine and ketamine (previously described). They were immediately decapitated, 
and their brains were removed. Immediately, coronal slices (350 μm thick) were cut from 
the cerebrum on a Leica VT1200 vibratome and placed in artificial cerebrospinal fluid 
(aCSF) containing the following (in mM): 126 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 
NaH2PO4, 2 MgSO4, 2 CaCl2 and 10 glucose, pH 7.4.  Slices were then fixed in 4% 
paraformaldehyde at 4 degrees Celsius overnight and washed three times with phosphate 
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buffered saline (PBS). Three tumor containing slices per animal were incubated with 
DAPI for 45 minutes at room temperature, rinsed three times with PBS, and placed into 
number 1.5 glass bottom dishes (MatTek) for imaging. A coefficient of determination 
analysis was used to compare cells identified with CRM to cells labeled with DAPI. 
Rodents utilized for molecular experiments (n=2) were deeply anesthetized using 
xylazine and ketamine and rapidly decapitated. Whole brains were placed in ice cold 
aCSF and sectioned into 1mm coronal sections using a rodent brain block. The cerebrum 
from each section was blocked into 4 equivalent sections. Two sections were 
immediately frozen in liquid nitrogen (LN2) for reference. At 15, 30, 45, 60, 90, and 
120minutes two sections were placed into glass bottom dishes. At each time point, the 
cortex, corpus callosum, and caudate/putamen from one section was imaged with CRM. 
As a control, one section was simultaneously placed on the stage of the microscope but 
not imaged. Each section was frozen in LN2 and stored at -80° C for assessment of DNA, 
RNA, and protein.  
 
Imaging  
All samples were imaged in uncoated No.1.5 glass-bottom dishes (MatTek corp). 
CRM was conducted with a Zeiss invereted 710 laser scanning confocal microscope 
equipped with a 40x/1.2NA water emersion objective. For reflectance imaging, a 633-nm 
diode laser was raster scanned across the sample and reflected photons were collected by 
tuning the emission filters to allow photons with the same wavelength of the incident 
laser passage to the photomultiplier tube. For DAPI imaging, samples were excited with a 
405-nm diode laser and 430-490nm emission collected. The confocal aperture was set to 
  68 
one Airy unit for all imaging. The laser and gain values were set to fill the dynamic range 
of the photomultiplier tube, and the frame size was set to sample at nyquist. Images were 
collected in 12-bit format absent of nonlinear processing.  
 
DNA Isolation & Analysis 
 DNA was isolated from brain tissue using the QIAamp DNA Mini (Qiagen), per 
manufacter’s instructions. DNA was quantified using the Nanodrop Spectrophotometer 
(Thermo Scientific). Samples were loaded in equal concentrations (100 ng) in a 1% 
agarose gel with ethidium bromide and imaged on an Alpha Imager (Alpha Imager). 
 
RNA Isolation and Analysis 
 Tissue was homogenized in 500 ul Ambion’s Cell Disruption Buffer (Life 
Technologies) and subsequently isolated using Ambion’s mirVana kit (Life 
Technologies), per manufacturer's instructions. RNA concentrations were determined 
using the Nanodrop Spectrophotometer (Thermo Scientific) and provided information for 
the dilutions necessary to remain within the dynamic range of the Bioanalyzer. The 
integrity of the RNA was assessed using Agilent 2100 Bioanalyzer Nanochips (Agilent 
Technologies). 
 
Western Blot Analysis 
 Frozen tissue was sectioned on dry ice and protein lysate was made by placing 
brain sections into 750 ul Ambion’s Cell Disruption Buffer (Life Technologies); 
triturated using RNase-free pipettes; and sonicated using Covaris Sonolab at 2 X 5% for 5 
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seconds; 2 X 20% for 15 seconds; 2 X 20% for 15 seconds; 2 X 5% for 5 seconds 
(Covaris Inc).  
 Protein concentrations were quantified by BCA (Pierce, Thermo Scientific) and 
18 ug/lane was loaded in 4-12% NuPage Bis-Tris gels (Invitrogen) and run using NuPage 
electrophoresis reagents (Invitrogen). Protein was transferred onto Novex nitrocellulose 
membrane (Invitrogen) and thereafter incubated for an hour in blocking solution 
consisting of 5% bovine serum albumin (Sigma Aldrich) in tris-buffered saline with 0.1% 
Tween (Thermo Fisher Scientific). Primary antibodies were incubated for 12 hours at 4 C 
while secondary HRP-conjugated antibodies were incubated for 1 hour at room 
temperature. Blots were probed for AKT (1:1000; Cell Signaling; Cat#: 9272) and 
GAPDH (1:60,000; Millipore; Cat#: AB2302). Horseradish peroxidase (HRP)-
conjugated secondary antibodies were Anti-Rabbit (1:2000; Cell Signaling; Cat#: 7074) 
and Anti-Chicken (Millipore; Cat#:12-341). 
 Blots were developed by using Pierce SuperSignal Chemiluminescent Substrate 
(Thermo Fisher Scientific) per manufacturer’s instructions. Protein signal was detected 
on film (General Electric).  
 
Statistical Analysis 
 Coefficient of correlation (R
2
 value) was determined between DAPI stained nuclei 
and nuclei detected by RCM using Graphpad Prizm. Differences were considered 
statistically significant for probability of less than .05. The Agilent 2100 Bioanalyzer 
provided an RNA integrity number ( RIN) calculated algorithmically by including the 
28s/18s ribosomal RNA bands, the region before the peaks, signal areas, and intensities. 
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An elevated threshold baseline and a decreased 28s:18s ratio are both indicative of RNA 
degradation while high 28S and 18S ribosomal RNA peaks as well as a small amount of 
5s RNA or a RNA number of greater than 7.5 are indicative of intact RNA (Fleige and 
Pfaffl 2006). Image J was used to determine density (intensity) of bands on a western 
blot. Data analysis consisted of determining relative density. Results will be expressed as 
the means and mean square error (SEM) data with normal distribution that will be 
compared by one-way analysis of variance and student’s t-test. 
 
Clinical Samples 
This research was approved by the Institutional Review Board of St. Joseph's 
Hospital and Medical Center and Barrow Neurological Institute, Phoenix, Arizona, where 
all surgery was performed. Preoperatively, patients signed an informed consent for 
participation.  Samples (mean size, 4 x 2 x 2 mm) were obtained at the time of 
craniotomy from within the tumor mass at a location determined to be safe by the 
surgeon. Tissue samples were placed in ice-cold aCSF and transported from the operating 
room to the pathology-based CRM system. There, the samples were immediately placed 
in #1.5 glass-bottom dishes (MatTek) and imaged. Investigators conducting imaging 
experiments were unaware of the pathological diagnosis at the time of imaging. Final 
diagnosis was determined by traditional immunohistochemistry and paraffin-embedded 
hematoxylin and eosin staining of the sampled tissue.  For the purpose of comparisons, 
the histopathological diagnosis made by a board-certified neuropathologist was accepted 
as the final diagnosis.   
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Results 
Reflectance imaging differentiates neoplastic cellular tumor from acellular tissue. 
 To investigate the potential of reflectance imaging for differentiating cellular 
tumor biopsies from acellular biopsies, we imaged acute slices generated from rodents 
intracranially implanted with human glioma cells. We incubated slices with DAPI to 
label all cell nuclei, then sequentially imaged the slices with CRM and LSCM (n=15 
slices from 5 animals). We collected five images per acute slice and compared cells 
identified with CRM to cells identified with DAPI. We found CRM provided definitive 
contrast between cell nuclei, cytoplasm, and extracellular tissue. Within tumor regions, 
CRM provided contrast to visualize hypercellular regions and relatively acellular regions 
with isolated cell populations (Fig1. A-C & E-G). In hypercellular and acellular regions 
we found CRM contrast correlated with r
2
=0.97 and r
2
=.098; respectively, to cells labeled 
with DAPI (Fig1. D&H).   
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Figure1: Reflectance  confocal imaging identifies cellular tumor in rodent acute slices.  
Cellular Tumor (A-D).  (A) Reflectance image of rodent xenograft tumor region; note 
shading of cell nuclei. (B) Dapi stain of identical tumor region identifies all cells in the 
field of view. (C) Overlay shows location of cells contrasted by reflectance to cells 
labeled with dapi. (D) Plot of coefficient of determination and confidence intervals for 
tumor cells identified by reflectance imaging. r
2
=0.97.  Cellular tumor and acellular tissue 
interface (E-H).  (E) Reflectance image of cellular tumor and adjacent acellular region 
from rodent xenograft; note isolated cell populations. (F) Fluorescence confocal image of 
identical region labeled with dapi. (G) Overlay of reflectance and fluorescence images 
from tumor and peritumoral tissue interface. (H) Plot of coefficient of determination and 
confidence intervals for cells identified by reflectance imaging at tumor and interface 
acellular tissue interface. r
2
= 0.98. Scale bar equals 20um  
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Reflectance imaging does not alter the molecular characteristics of examined tissue. 
 To determine if CRM alters the molecular characteristics of tissue, we examined 
DNA, RNA, and protein from tissue imaged with CRM to tissue immediately frozen for 
analysis and compared that with tissue that had reflectance imaging and was left out for 
varying amount of time. Although the typical time from surgical resection to reception in 
pathology and assessment using CRM typically takes 15 minutes, we tested out to 180 
minutes. Neoplastic tissues are heterzyogous in terms of cellularity and gene and protein 
expression and may yield inter-specimen molecular variability. Therefore, we conducted 
these experiments on control tissue harvested from rodent normal brain.  
  DNA quality was assessed in CRM imaged samples, which showed no difference 
compared to immediately frozen controls. Discrete DNA bands were detectable up to 180 
minutes after extraction (Fig. 2B) suggesting no degradation of DNA elements. RNA 
integrity number (RIN) was generated to determine the integrity of isolated RNA. RIN 
number of 1 suggests strong degradation while RIN greater than 8 suggest minimal 
degradation (Fleige and Pfaffl 2006). RIN number was comparably the same between 
control and CRM imaged groups (Figure 2C), indicating no effect of CRM on RNA 
integrity of imaged samples. RNA integrity remained the relatively the same up to 120 
minutes post-biopsy. There was a slight decrease over time in RIN value that was similar 
for both the control and CRM tissue, most likely due to RNases within the tissue over 
time. Protein kinase B (AKT), a protein involved in GBM pathogenesis, was examined 
for potential damage post-imaging with CRM. Western blot analysis of extracted tissue 
showed that up to120 minutes post-extraction, discrete AKT bands were detectable and 
contained similar density to control samples (Fig. 2E).  
  74 
 
Figure 2: CRM does not alter DNA, RNA, or protein of examined tissue.A) CRM image 
of fresh brain tissue at cerebral cortex 90 minutes post-excision. Scale bar equals 20um. 
B) Gel electrophoresis of genomic DNA extracted from  control and CRM imaged 
biopsies; note similar bands across time course. C=control and R= CRM. between 
imaged and control biopsies. C) Time course comparison of RNA integrity for all imaged 
and control samples; note similar RNA integrity for all samples. D) Western blot analysis 
showing expression of AKT over 120-minute time course. Protein signal did not degrade 
over time course or when exposed to CRM.  R= Confocal Reflectance Microscopy, C= 
Control.  
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CRM differentiates human cellular from acellular brain tumor biopsies. 
  To test the ability of CRM to differentiate cellular tumor from acellular tissue 
samples in a clinical setting, we imaged two fresh human brain tumor biopsies; one 
yielding radiation necrosis tissue. Tissue samples were placed in ice-cold aCSF and 
imaged with CRM. Imaging time per sample was less than 2 minutes. Samples were then 
compared to final histpathological diagnosis.  
 Similar to our findings in rodent xenografts, we found that CRM contrasted 
cellular regions from acellular regions in human biopsies. Tissue samples identified as 
cellular with CRM were found to be cellular with proceeding standard histopathological 
assessment (Figure3 A,C). CRM failed to identify cellular regions in necrotic tissue 
samples (Figure3 B,D).  
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Figure3: Reflectance imaging immediately identifies cellular and necrotic fresh human 
brain tumor biopsies. (A-C) Glioblastoma.  A) Low magnification CRM image of ex vivo 
human GBM biopsy imaged with CRM. B) High magnification of cellular region 
identified from inset of A, note arrowheads identifying cells within region. C) 
Corresponding H&E image.  (D-F) Necrotic  sample.  D) Low magnification image of ex 
vivo  necrotic biopsy imaged with CRM. E) High magnification inset from D. Note lack 
of distinct cells. F) H&E from corresponding section. Scale bar equals 20um.  
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Discussion: 
 Our data illustrate confocal reflectance microscopy’s utility as a safe and rapid 
technique for identifying the cellularity of glioma tissue prior to biobanking. This 
imaging modality can be immediately utilized on fresh tissue samples without application 
of exogenous contrast agents and without altering the molecular characteristics of 
examined tissue. CRM can provide a much needed tool for neurosurgery-neuropathology 
teams by maximizing the quality of tissue samples collected during surgical resection. 
Although other imaging modalities may provide excellent images, their greater energy 
input and the possible need to use exogenous fluorophores could affect future molecular 
analysis of the tissue (Liao, Tsytsarev et al. 2013).  
We found CRM did not alter the DNA, RNA, or protein that could be extracted 
and quantified from tissue biopsies screened up to 2 hours after resection. CRM images 
collected from these samples could be digitally stored and potentially recalled with 
biobanked specimens. We found CRM may have diagnostic utility, as many images 
revealed distinct morphological details such as; cellularity, vasculature, and necrosis 
(Figures 1and 3) typically identified with traditional histopathological H & E staining.  
Many translational neuro-oncology studies rely on human GBM tissue samples 
that appropriately represent an original tumor. Unintentional utilization of necrotic or 
non-representative tissue samples in studies can lead to erroneous results that will not 
improve our knowledge of the disease. In studies that advance to clinical trials, patient 
biopsies are often screened to determine eligibility for a targeted clinical trial. CRM’s 
nondestructive tissue assessment can ensure patients are not mistakenly excluded from 
potential life-prolonging treatments, particularly when standard therapy has failed. 
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Screening for high quality tissue specimens with CRM can facilitate the advancement of 
our knowledge of gliomagenisis, and can ensure qualified patients receive potential life-
prolonging therapies (Rainov and Heidecke 2011).  
 Current limitations of CRM include limited imaging depth penetration. With our 
imaging parameters, CRM could assess tissue from the surface to 200-300 microns 
within. However, we did not find this limitation altered the accuracy of tissue assessment 
in our studies. Additionally, few pathology departments currently contain the imaging 
hardware or personnel required to screen tissue biopsies with CRM. Modernization of 
pathology departments may include addition of confocal microscopes and other systems 
capable of CRM that will allow the screening of samples within two-hours time. Lastly, 
ex vivo CRM is limited by the ability to only assess tissue that is intraoperatively selected 
to represent tumor. A hand held intraoperative CRM device could potentially overcome 
human sampling error and allow assessment of tissue samples prior to resection.   
CRM technology has shown utility in providing cellular and subcellular detail, 
specifically in diagnosing dermatological conditions, identifying neoplastic tissue and 
margins, and assessing diseased and normal liver tissue (Rajadhyaksha, Gonzalez et al. 
1999, White, Tearney et al. 2000, Campo-Ruiz, Ochoa et al. 2002, Clark, Gillenwater et 
al. 2003, Drezek, Richards-Kortum et al. 2003, Gonzalez, Swindells et al. 2003, Hicks, 
Swindells et al. 2003, Curiel-Lewandrowski, Williams et al. 2004, Campo-Ruiz, Lauwers 
et al. 2005). Our study is the first to assess human brain tumor biopsies with CRM for 
biobanking purposes. By quantifying DNA, RNA, and protein, we also demonstrate for 
the first time CRM’s ability to assess tissue cytoarchitecture without altering tissue 
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molecular integrity, meaning that no part of the tissue to be banked needs to be discarded 
in the assessment process.  
Conclusion 
Confocal reflectance microscopy can screen brain tumor tissue cellularity for 
inclusion into biobanks while preserving the molecular integrity of tissue samples. CRM 
provides a rapid imaging modality that can accurately provide ex vivo morphological 
information in animal models and fresh human biopsies. In comparison to traditional 
histopathological methods, this technique does not rely on exogenous dyes or fixation 
and sectioning. Furthermore, this technique preserves the DNA, RNA, and protein 
characteristics of tissues, allowing further analysis of imaged specimens. Future technical 
developments of CRM include utilization of a handheld confocal endomicroscope for 
imaging, which would allow rapid and safe histopathological assessments in vivo. Further 
applications of CRM may include rapid ex vivo and in vivo examination of brain tumors 
in addition to glioblastoma. This technique ensures that high quality specimens are 
biobanked for future molecular studies of tumor samples and for assessing patient 
eligibility for clinical trials based on tumor characteristics.  
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CHAPTER 4 
RAPID AND SPECIFIC DIAGNOSIS OF HUMAN ASTROCYTIC BRAIN TUMORS 
BY IMMEDIATE EX VIVO IMAGING WITH SULFORHODAMINE 101 
 Brain tumor resection is guided by intraoperative diagnostics. However, current 
histopathological techniques lack the specificity and speed required to be effective 
intraoperative diagnostic tools.  Here we show that imaging of fresh human brain tumors 
rapidly labeled with the physiological fluorophore sulforhodamine 101 (SR101) can 
differentiate astrocytic tumors, reactive astrocytes and tumor margins from non-astrocytic 
brain tumors and normal brain.  Acute slices from orthotopic human glioma (n=8) and 
lymphoma (n=6) xenografts were incubated with SR101 or its fixabale analog and 
imaged with confocal microscopy. A subset of slices (n=18 slices) were respectively 
counter-immunostained with GFAP and CD20 for stereological assessment of SR101 co-
localization. Additionally, sixty-five undiagnosed fresh human samples were examined 
by quickly incubating with SR101, immediately imaging, and comparing to final 
pathological diagnosis. SR101 differentiated astrocytic tumor cells from reactive 
astrocytes and lymphoma cells. In acute slices, SR101 labeled 86.50% (+/-1.86; 
p<0.0001) of astrocytoma cells and 2.19% (+/-0.47; p<0.0001) of lymphoma cells. In 
human biopsies, SR101 rapidly labeled reactive astrocytes and selectively identified 12 of 
13 astrocytomas without labeling non-astrocytic tumors. SR101 rapidly and selectively 
labels human astrocytic tumors and astrocytes in a time frame that supports intraoperative 
decision-making. This is the first reported use of a functional dye on living human brain 
tumor tissue to provide a clinically meaningful immediate histopathological diagnosis. 
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Clinical application of SR101 could improve intraoperative decision-making, ultimately 
improving patient care. 
 
Introduction 
Intraoperative histopathological diagnosis guides the surgical resection strategy 
for numerous cancers, including intrinsic brain tumors such as astrocytomas.  However, 
frozen-section analysis, the method of choice for obtaining such diagnoses, often 
produces artifacts and provides only limited nonspecific information about tissue based 
on its morphology and cellular architecture (Gal 2005, Lechago 2005).  When an accurate 
intraoperative diagnosis cannot be obtained, clinical teams must wait for postoperative 
antibody staining of biopsied tissue to identify its specific molecular markers, a process 
that often requires 24-72 hours.  Consequently, the inability of the frozen section to 
consistently provide rapid and specific information can limit definitive intraoperative 
surgical planning.  Furthermore, while rapid identification of the tumor core is important 
for diagnosis, identification of the tumor margin is most critical for guiding astrocytoma 
resection. 
Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most common 
subtype of astrocytoma with a median survival of 12-15 months (Wen and Kesari 2008).  
Length of survival is directly related to extent of GBM tumor resection, which is based 
on frozen-section analysis of biopsied tissue to identify tumor margins (Lacroix, Abi-Said 
et al. 2001, Powell 2005, Pichlmeier, Bink et al. 2008).  In contrast, definitive resection 
of the common central nervous system (CNS) tumor, CNS lymphoma, remains 
contraindicated; diagnostic biopsy alone is the most common reason for surgical 
  84 
intervention. GBM and lymphoma have similar clinical presentations, and can be difficult 
to differentiate on diagnostic imaging (Ferreri, Reni et al. 2009, Ricard, Idbaih et al. 
2012). Consequently, clinical decision-making depends on tissue biopsy and 
histopathological analysis. Furthermore, frozen-section analysis often fails to be 
diagnostic, necessitating the need for postoperative antibody staining of resected brain 
tissue. Glial fibrillary acidic protein (GFAP) is a useful immunohistochemical tool, which 
combined with cellular morphology assists in the diagnosis of astrocytomas. GFAP 
positivity supports the diagnosis of GBM, whereas CD20 positivity supports a diagnosis 
of CNS B-cell lymphoma.  Although effective, such postoperative staining requires 24 
hours to obtain a diagnosis—too slow to guide intraoperative decision-making.   
Although its underlying mechanism is incompletely understood, SR101 is a red 
fluorescent dye used in neuroscience research for the rapid and specific labelling of 
astrocytes (Nimmerjahn, Kirchhoff et al. 2004, Kafitz, Meier et al. 2008).  Similar to 
GFAP, SR101 labels astrocytic cells, and it has been used to label rodent astrocytoma 
cells in culture (Lai, Bechberger et al. 2007).  If SR101 also labels GBM and other cells 
of astrocytoma lineage, it could provide a clinical alternative to GFAP for differentiating 
GBM from lymphoma during intraoperative diagnosis.  We hypothesized that the 
combined use of live-cell imaging with targeted fluorophores could improve the current 
standard of care by providing rapid and specific intraoperative diagnoses of astrocytic 
tumors. Specifically, we evaluated the utility of sulforhodamine 101 (SR101) to rapidly 
distinguish tumor type and neuropathological diagnosis of astrocytoma in cell culture, 
animal tumor models, and freshly resected human brain tumors.   
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Materials and Methods 
Cell culture 
We acquired human glioma cell line U251 and human CNS lymphoma cell line 
MC116 from American Type Culture Collection (ATCC). The cell lines were maintained 
in culture with Dulbecco’s Modified Eagle Medium (DMEM)  media supplemented with 
10% fetal bovine serum, and Roswell Park Memorial Institute Medium (RPMI) 1640 
media supplemented with 20% FBS (all from Invitrogen, Grand Island, NY). Cells were 
grown at 37°C in a humidified incubator under 5% CO2.  
In Vitro SR101 labeling 
U251 glioma cells were labeled by incubating 100,000 cells on a collagen-coated 
glass-bottom dish (MatTek). After 24 hours, the medium was replaced with artificial 
cerebrospinal fluid (aCSF) containing 2 μM SR101 (Sigma) for 20 minutes, followed by 
two 5-minute washes with standard aCSF.  
 
Animals  
Fifteen male Crl:NIH-Foxn1
rnu
 rats (5 weeks age) were obtained from The 
Charles River Laboratories International, Inc. (Wilmington, MA). Experiments were 
performed in accordance with the guidelines and regulations set forth by the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee of the Barrow 
Neurological Institute of St. Joseph’s Hospital and Medical Center, Phoenix, Arizona.  
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Intracranial implantation  
The rats were anesthetized by intramuscular injection of a mixture of 10 mg/kg 
xylazine and 80 mg/kg ketamine (Wyeth, Madison, NJ) and placed in a small animal 
stereotactic headframe (Model 900, David Kopf Instruments, Tujunga, CA). A 10-mm 
incision was made starting between the animal’s eyes to expose bregma. A bur hole was 
made 3.5 mm lateral to bregma. U251 (n=9 rats) or MC116 cells (n=6 rats) were infused 
at a depth of 4.5 mm below the surface of the brain after the syringe (Hamilton) was 
advanced 5.0 mm to create a 0.5-mm pocket. The cell suspension was infused using a 
UMP3-1 UltraMicroPump microinjector (WPI, Sarasota, FL) set to a volume of 10 µL 
with an infusion rate of 3.00 µL/minute. The needle was withdrawn 2 minutes after the 
injection to minimize backflow of the cell suspension. The bur hole was covered with 
bone wax, the skin incision was sutured, and the rats were allowed to recover.  
 
Acute slices 
Twenty-eight days after implantation, rats were deeply anesthetized using the 
xylazine/ketamine mixture as described previously. They were immediately decapitated, 
and their brains were removed. Immediately, coronal slices (350 μm thick) were cut from 
the cerebral cortex on a Leica VT1200 vibratome in aCSF containing the following (in 
mM): 126 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 2 CaCl2 and 10 
glucose, pH 7.4.  Slices were then incubated at room temperature in aCSF containing 
2μM SR101 for 20 minutes followed by a 10-minute wash in aCSF. A two-tailed paired 
t-test with alpha set to 0.05 was used to compare mean fluorescence intensity (MFI) 
between tumor cells and reactive astrocytes. 
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Co-labeling 
SR101 is not amenable to fixation; we therefore used a fixable version of 
SR101(Texas Red Hydrazide) for these experiments. The staining pattern of fixable 
SR101 fluorophore mimics the staining pattern of the standard nonfixable SR101 
(Nimmerjahn, Kirchhoff et al. 2004, Kafitz, Meier et al. 2008).  For clarity, the use of the 
fixable version of SR101 is clearly indicated by the term “fixable SR101” throughout the 
text.   Fixable-SR101 and the nonfixable version had similar staining patterns, but the 
intensity and cellular staining of the fixable version was weaker than that of the standard 
SR 101. 
Acute xenograft slices were incubated with the fixable version of SR101 (Texas 
Red Hydrazide; Sigma), washed at room temperature, and fixed with 4% 
paraformaldehyde for 12 hours at 4° C. The sections were rinsed in phosphate-buffered 
saline, permeabilized with 0.3% triton, and blocked with CAS block (Invitrogen) 
(Beeman, Georges et al. 2013). The GBM xenograft slices (9 slices from 3 animals) were 
incubated in anti-GFAP primary antibody (Millipore; 1:500) for 12 hours, and the 
lymphoma sections (9 slices from 3 animals) were incubated in anti-CD20 primary 
antibody (Millipore; 1:250) for 12 hours. Sections were then rinsed and incubated with 
AlexaFluor488 secondary antibody (Invitrogen), followed by DAPI (Invitrogen) nuclear 
counterstain and mounted on slides with vectashield (Vector labs) and No 1.5 coverslips 
(VWR).  
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Stereology 
We adapted standard stereology approaches to quantify tumor cells labeled with 
fixable- SR101 and GFAP or CD20 antibodies (Mouton 2002, Kim, Lee et al. 2010).  We 
selected one rostral, midline, and caudal acute slice from each brain containing tumor 
incubated with fixable SR101. Glioma slices were immunofluorescently stained for 
GFAP, and slices containing lymphoma were stained for CD20. In each slice, 10 
randomly selected region of tumor (150 μm2) were optically sectioned to 50 μm with a 
Zeiss 710LSM. The first 5 μm of each image stack was discarded to minimize counts 
from cells damaged during sectioning. A maximum intensity projection image was 
generated from the remaining 45 μm, and a stereology dissector was overlaid onto the 
image. Cells within the dissector and those in contact with its left and bottom edges were 
counted for either GFAP or CD20 positivity and for SR101 positivity.  
The percent overlap between immunostaining and SR101 positivity was 
calculated. Two-tailed t-tests with alpha levels of 0.05 were used to determine statistical 
differences. A paired t-test was used to determine if staining localization between 
antibody- and SR101-labeling differed between cell types.  An unpaired t-test was used to 
compare fixable-SR101 staining between glioma and lymphoma models. 
 
Human Samples  
This research was approved by the Institutional Review Board of St. Joseph's 
Hospital and Medical Center and Barrow Neurological Institute, Phoenix, Arizona, where 
all surgery was performed. Preoperatively, 65 patients with one of 11 common brain 
tumors (Table 1) signed an informed consent for participation.  Samples (mean size, 4 x 2 
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x 2 mm) were obtained at the time of craniotomy from within the tumor mass at a 
location determined to be safe by the surgeon.  The diagnosis was determined by 
traditional immunohistochemistry and paraffin-embedded hematoxylin and eosin 
staining.  For the purpose of comparisons, the histopathological diagnosis made by a 
board-certified neuropathologist was accepted as the final diagnosis.   
Tissue samples were placed in ice-cold aCSF containing 2 μM of SR101 and were 
transported from the operating room to the laboratory. There, the samples were rinsed 
with aCSF (10 minutes), and imaged within 30 to 40 minutes of biopsy. Investigators 
conducting imaging experiments were unaware of the pathological diagnosis. 
 
Imaging 
SR101-labeled samples were placed in uncoated No.1.5 glass-bottom dishes and 
positioned on the stage of a Zeiss 710 laser scanning confocal microscope equipped with 
a 40x/1.2NA water emersion objective. We imaged SR101 by exciting the fluorophore 
with a 561-nm diode laser and collecting 595-nm to 625-nm emissions. The confocal 
aperture was set to Airy unit for all imaging. The laser and gain values were set to fill the 
dynamic range of the photomultiplier tube, and the frame size was set to sample at 
Nyquist. Images were collected in 8- and 12-bit format absent of nonlinear processing. 
An unstained adjacent tissue sample was imaged with each sample. In some cases, large 
field-of-view tiled and optically sectioned images were rapidly acquired using a Zeiss 
line-sweeping confocal microscope. For this system the frame size was fixed at 512 x 512 
by a linear charged-coupled device array.      
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Results 
SR101 labels human astrocytoma cells and reactive astrocytes 
To investigate the potential of SR101 for identifying human astrocytoma cells, we 
used differential interference contrast (DIC) with fluorescence overlay to image human 
astrocytoma cell line U251 after incubation in SR101 (n=6 cultures).  The fluorophore 
filled the cytoplasm of the cultured cells and clearly delineated cell nuclei (Figs. 1A, B).  
Next, human astrocytoma cells (U251 cell line) were implanted into the caudate-
putamen of 5 nude rats and allowed to grow for 4 weeks before the rats were sacrificed.  
This orthotopic xenograft model consistently produced astrocytic tumors as previously 
characterized (Michaud, Solomon et al. 2010, Buckingham, Campbell et al. 2011).  Live 
cell confocal images of acute slices from the cerebral cortex of the implanted animals 
(Fig. 1C) treated with SR101 showed cells in the tumor core markedly labeled with the 
fluorophore. The cells were easily distinguished from low level background staining 
(Figs. 1D, E, F).   
Confocal microscopy imaging of the acute slices treated with SR101 also showed 
distinct tumor margins that contained SR101-positive astrocytoma cells and reactive 
astrocytes (Figs. 1G, H). The fluorescence intensity from the astrocytoma cells and 
reactive astrocytes was quantified. The mean fluorescence intensity did not differ 
between the two cell types (Fig. 1I). However, reactive astrocytes were easily 
distinguished based on their distinct morphology (Fig. 1H).  Therefore, SR101 can 
rapidly identify astrocytes and astrocytoma cells in cell culture and animal models, and it 
can effectively define tumor margins in an animal model.   
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Figure1: Non-fixable SR101 labels human astrocytoma cells in culture and identifies 
tumor core and margin in rodent xenografts. U251 Astrocytoma Cell Culture (A-B).  (A) 
DIC image with fluorescent overlay of human U251 astrocytoma  cells incubated with 
SR101.  (B)  Inset showing cytoplasmic filling of cells and delineation of cell nuclei 
(arrowheads).  Acute slices from rodents intracranially implanted with U251 cells (C-H).  
(C) Acute slice containing U251 derived tumor. Representative core and margin regions 
identified by white circle and green circle respectively.  (D) Confocal fluorescence image 
of  SR101-labeled tumor core.  (E) High magnification of inset showing typical 
morphology of U251cells.  (F) Histogram of SR101 fluorescence distribution in E 
between tumor core and background.  Note the clear distinction in mean fluorescence 
intensity (MFI) between tumor (102.84) and background (8.74).  (G) Image of tumor 
margin with SR101 labeled cells.  (H) Inset of morphologically identified reactive 
astrocyte (arrow) surrounded by glioma cells (arrowheads) near the tumor margin.  (I) 
Mean fluorescence intensity of U251 cells and reactive astrocytes normalized to 
background (n=9 optical sections from 3 acute slices).  Note no statistically significant 
difference in MFI between the two cell types. Scale bar equals 20um  
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Fixable SR101 labels GFAP-positive human astrocytoma cells and reactive astrocytes 
We used confocal microscopy to compare the efficacy and localization of SR101 
and GFAP staining.  Confocal images from the tumor core regions showed numerous 
cells simultaneously filled with fixable-SR101 and labeled by GFAP (Fig. 2A-D).  In 
general, GFAP and SR101 labeled the same cells, although fixable-SR101 stained some 
cellular processes less intensely than GFAP (Figs. 2A, B, D).  Merged images from the 
tumor core showed that most cells were positive for both fixable SR101 and GFAP, 
indicating that SR101 effectively labels astrocytic tumor cells.   
We compared the staining pattern of fixable-SR101 and GFAP to determine if 
reactive astrocytes could be differentiated from neoplastic astrocytes to help identify 
tumor borders. Imaging of rat brain regions adjacent to human astrocytoma cells showed 
that the staining patterns of fixable-SR101and GFAP were similar (Figs. 2E, F). 
However, GFAP labeled membrane processes more thoroughly than the fixable-SR101. 
Cells in the peripheral regions contained extensive membrane projections that could be 
readily differentiated from cells within the tumor core that lacked this feature. When 
additional cells in these regions were stained with 4’,6-diamidino-phenylindole (DAPI) 
(Fig. 2G), groups of cells were negative for both fixable-SR101 and GFAP (Figs. 2G, H, 
arrows). These findings suggest a mixed cell population of tumor cells and nontumor 
brain cells typical of regions outside the tumor core. Together, the data indicate that 
SR101-positive cells are the GFAP-positive astrocytoma cell population.  Furthermore, 
fixable-SR101 provides morphological information that appears to differentiate 
astrocytoma cells from reactive astrocytes. 
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Figure 2: Fixable SR101 colocalizes with the astrocytic marker GFAP. Confocal imaging 
of  rodent xenograft acute slices incubated in the fixable version of SR101. Following  
incubation slices were fixed and stained with GFAP and Dapi.  Images taken from  the 
core of the astrocytoma (A-D).  Fixable SR101 fills the cell bodies of GFAP-positive 
cells in the tumor core, and weakly fills astrocytic processes (arrows).   Note the 
significant overlap of GFAP, DAPI and SR101 in the merged image.  Images taken from 
the margin of the astrocytoma (E-H) . Fixable SR101 fills cell bodies of GFAP-positive 
cells at the tumor margin. Solid arrows identify SR101 and GFAP positive cells.   Note 
the appearance of DAPI positive cells (arrowheads) unlabeled by SR101 or GFAP that 
are selectively observed at the astrocytoma margin.  Scale bar equals 20um. 
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SR101 differentiates astrocytoma from lymphoma 
 In contrast to the findings from astrocytoma cells, confocal imaging indicated 
minimal SR101 signal from the human CNS lymphoma cell line MC116 (Supplemental 
Fig. 1). In acute slices from astrocytoma and CNS lymphoma animal models incubated 
with fixable-SR101, we quantified co-localized GFAP for astrocytoma slices and CD20 
for lymphoma slices. In astrocytoma tumor regions, fixable-SR101 labeled the majority 
of cells (Figs. 3A-D, I).  The frequency of co-localization of SR101 and GFAP was 
86.50% (Fig. 3K, Table 2), with a mean of 22.30 SR101-positive cells and 20.58 GFAP-
positive cells per stereology dissector region of interest (Lacroix, Abi-Said et al.) 
(p=0.0004, Fig. 3I, Table 2).  In contrast, fixable SR101 labeled only a very small 
number of cells from ROIs in CNS lymphoma acute slices (Fig. 3E).  SR101 and CD20 
co-localized poorly (2.19%), and there were significantly more CD20-positive cells than 
fixable-SR101-positive cells (p<0.0001) (Fig. 3J, Table 2).  However, SR101 labeled a 
small number of cells in CNS lymphoma tissue that were not CD20-positive and that 
morphologically resembled reactive astrocytes (Figs. 3E, F; arrow).  SR101 distinguished 
astrocytoma from lymphoma tissue and co-localized with GFAP more frequently than 
CD20 (Fig. 3K). This finding demonstrates the strong relationship of SR101 to GFAP-
positive cells in astrocytoma, and the ability of SR101 to differentiate it from a non-
astrocytic tumor such as CNS lymphoma. 
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Figure 3: SR101 rapidly differentiates human astrocytoma from CNS lymphoma in 
rodent xenografts.  Confocal imaging of acute slices taken from xenograft animals 
implanted with astrocytoma cells (U251)(van Dam, Themelis et al.) or lymphoma cells 
(MC116)(Middle).  Slices were stained with fixable SR101 and specific markers for 
Astrocytoma (GFAP) or Lymphoma (CD20) .  Nuclei were counterstained with DAPI.  
Top:  Region from U251 astrocytoma acute slice incubated with fixable SR101 and 
counterstained with GFAP and DAPI (A-D).  Middle:  (E) SR101 labels a single cell 
(dashed arrow) in a MC116 xenograft lymphoma region.  (F) CD20  immunostaining 
labels lymphoma cells, but does not label region containing SR101-positive cell (solid 
arrow).  (G) DAPI counterstain of cell nuclei in field of view. (H) Merged lymphoma 
image indicating poor colocalization of SR101 and CD20. Scale bar equals 20um.  
Bottom:  Confocal stereology of acute slices (see Methods).  (I) Number of SR101 and 
GFAP-positive cells present in U251 xenograft astrocytoma regions are not statistically 
different (p<0.01).  (J) Number of SR101 and CD20 -positive cells present in MC116 
xenograft lymphoma regions are highly statistically different (P<0.01*).  (K)  SR101 
significantly overlaps with GFAP positive astrocytoma cells (79.6% ) compared with 
CD20 lympoma cells (1.97% )(p<0.01).   
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Supplemental 1: Non-Fixable SR101 does not label human lymphoma cells in rodent 
xenografts. (Verkman, Hara-Chikuma et al.) SR101 labeled acute slices prepared from 
rodent CNS lymphoma xenografts. (A) SR101 sparsely labels a minimal number of cells 
within the tumor region. (B) Non-specific acridine orange staining reveals a hypercellular 
tumor region. (C) Overlay image shows incomplete cytoplasmic filling of cells with 
SR101 staining. Scale bar equals 20um. 
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SR101 intraoperatively differentiates human astrocytoma from other human CNS 
neoplasms   
We studied the utility of SR101 as a broad-spectrum neurosurgical intraoperative 
diagnostic agent by intraoperative identification of astrocytic brain tumors with 
fluorescence imaging of fresh human brain tumor biopsies labeled with SR101. In brain 
without tumor, SR101 filled the cytoplasm of cells that morphologically resembled 
astrocytes (Fig. 4A). In astrocytic tumor cores, SR101 stained cytoplasm, was excluded 
from most cell nuclei, and distinguished nuclear atypia (Fig. 4C, D). The fluorescence 
detected in astrocytes and astrocytoma cells was not endogenous autofluorescence 
(Supplemental Fig. 2). In non-astrocytic tumor samples, SR101 exclusion outlined the 
location of cell bodies but did not fill cytoplasm (Figs. 4E-I).  One GBM case did not 
stain with SR101. Final neuropathological diagnosis of this case indicated the examined 
tissue consisted mostly of radiation treatment effect and not cellular GBM.  
Interestingly, SR101 did not label most oligodendroglioma samples, although 
these tumors are often positive for GFAP.  This finding suggests that SR101 also may be 
helpful for distinguishing oligodendrogliomas from other gliomas (Fig. 4H).  SR101 
failed to stain human lymphoma but labeled reactive astrocytes within the tissue, 
supporting the findings from our CNS lymphoma animal model (Fig. 4I, Supplemental 
Fig. 3).  
Together, these data show that SR101 exhibits marked specificity for human 
astrocytes, astrocytomas, and reactive astrocytes. SR101 staining coupled with confocal 
microscopy allowed human astrocytic tumors and margins as well as reactive astrocytes 
to be identified within a time frame that supports intraoperative decision-making.   
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Figure 4: SR101 selectively labels human astrocytes and astrocytic brain tumors.  Human 
brain tumor biopsies rapidly stained with SR101 and imaged with a confocal microscope. 
(A) Cell with astrocytic morphology from human brain labeled with SR101. (B) GBM 
margin with morphologically distinct tumor cells and reactive astrocytes  (C) Grade IV 
astrocytoma. (D) Inset from C; hypercellularity and nuclei (arrowheads) are evident . (E-
G)  Non-astrocytic tumors absent of cells cytoplasmically filled with SR101.  Dark 
regions in tissue indicate location of cell bodies. (G) Oligodendroglioma does not stain 
with SR101. (H) Lymphoma is negative for SR101 staining. Scale bar equals 20um 
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Supplemental 2: Endogenous fluorophores in human ex vivo tissue do not contribute to 
SR101 fluorescence. (A) Spectral imaging of human samples stained with SR101 
generates a single emission profile unique to SR101. Note absence of additional emission 
spectra suggesting minimal contribution of endogenous fluorophores to the overall 
fluorescence signal. (B) Red crosshairs indicate SR101 positive cell selected for spectral 
analysis.     
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Supplemental 3: SR101 identifies reactive astrocytes in a human lymphoma biopsy. (A) 
Tiled image of human CNS lymphoma composed of 53 500um
2
 optical sections contains 
SR101 positive cells with extensive processes. (B) High magnification inset 
morphologically clarifies SR101 positive cells as reactive astrocytes. Note lack of 
additional cell morphologies positive for SR101. (C) Non-specific acridine orange 
staining from adjacent biopsied region shows hypercellular tissue containing a 
heterozygous cell population. Scale bar equals 20um. 
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Discussion 
We have demonstrated a technique for identifying the most common primary 
brain tumor, astrocytoma, by ex vivo exposure to the fluorescent dye SR101. This 
technique can provide specific cellular and molecular information necessary for diagnosis 
during surgery. We tested the specificity of SR101 in human cell culture, orthotopic 
rodent xenografts, and human tumor samples. Compared to the current standard of 
immunocytochemistry and final pathological paraffin-embedded diagnoses, SR101 
provided more rapid and equally accurate identification of astrocytic tumors in all model 
systems. In human samples, SR101 provided effective visualization and differentiation of 
astrocytic tumors and, most importantly, their margins.     
Improvements in timely and accurate intraoperative diagnoses are profoundly 
needed in clinical neurosurgery. Current diagnostic techniques rely on visualization of 
tissue with standard light microscopes and conventional contrast agents, a process that 
has evolved little over the last century (Gal 2005, Lechago 2005).  Here, we have shown 
that fluorescent labeling of ex vivo tissue coupled with confocal imaging provide clear 
diagnostic benefits compared with current techniques. Our technique allows visualization 
of pathological tissue without freezing, fixing, or sectioning with their attendant artifacts 
and tissue loss (Supplemental Fig. 4). Images from tissue can provide a diagnosis within 
minutes—well within a time frame required to effectively guide a surgical approach and 
influence a patient’s care while surgery is still in progress.  
We envision that fluorescence imaging of ex vivo tissue will become a common 
technique in pathology departments in the near future.   Our results here have clearly 
indicated the potential utility of SR101 for meeting the important clinical need of 
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differentiating high-grade astrocytoma from CNS lymphoma.  Although the macroscopic 
appearance of these tumors is similar intraoperatively, their treatment plans are markedly 
distinct (Ricard, Idbaih et al. 2012). Astrocytomas require maximal safe resection to 
provide survival benefits to patients, while lymphomas are best biopsied and treated with 
adjuvant therapy. Differentiating these tumors requires a surgical biopsy followed by a 
minimum of 24 hours for diagnostic processing. We found these tumors could be 
differentiated by SR101 staining and confocal microscopy within 30 minutes of biopsy. 
This information could allow rapid modification of a surgical plan with consequent 
improvement of clinical outcomes.   
GBM contains a heterozygous population of cells that vary in terms of GFAP 
expression (Bonavia, Inda et al. 2011). SR101 labeled slightly more tumor cells in GBM 
xenografts than GFAP. This finding resembles data from normal brain showing that 
SR101 identifies subtypes of astrocytes and precursor cells that are GFAP negative 
(Kimelberg 2004, Kafitz, Meier et al. 2008). Future studies on SR101 are required to 
identify and characterize GBM precursor cells that uptake SR101. Furthermore, a direct 
comparison of the sensitivity of SR101 and GFAP in human brain tumors is warranted. 
Probes and devices that allow microscopic visualization and diagnosis of deep in 
vivo structures are under development (Michalet, Pinaud et al. 2005, Rivera, Brown et al. 
2011, Kircher, de la Zerda et al. 2012). Some in vivo fluorescence imaging instruments 
have already been tested clinically (Eschbacher, Martirosyan et al. 2012). Safety 
concerns, however, may preclude some fluorophores and imaging modalities from ever 
being approved for in vivo clinical use. Nonetheless, rapid ex vivo diagnostics could 
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complement in vivo imaging by providing information from tissues processed with 
techniques that may not be safe for in vivo clinical use.   
There are important considerations to diagnostic use of SR101.  Staining with this 
agent requires tissue to be alive and relatively healthy when it is incubated with the dye.  
Damaged cells have been reported to uptake the dye (Masamoto, Tomita et al. 2012, 
Nimmerjahn and Helmchen 2012).  However, we encountered no significant false 
positives in our experiments.  A practical limitation to the widespread use of SR101 
includes the need for immediate incubation of resected tissue in the operating room. 
Furthermore, immediate ex vivo imaging using specific fluorescent probes is not yet part 
of clinical pathological practice. Therefore, few pathology laboratories have confocal 
microscopes. Modernization of pathology departments would be needed to overcome 
these limitations.   
 
Conclusion 
 SR101 rapidly and selectively labels human astrocytic tumors and astrocytes. To 
our knowledge, our results represent the first use of a functional dye on living human 
brain tumor tissue to provide a clinically meaningful immediate ex vivo histopathological 
diagnosis.  There is compelling reason to believe that this method is only the first foray 
into a broad new area of pathology that has become possible because of the rapid and 
dramatic advances in fluorescence probes and fluorescence imaging techniques.  
Application of this technique to other tumors and diseases will only be limited by the 
identification of specific molecular targets and the development of targeted fluorophores.  
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These imaging techniques may have profound implications for improving patient 
diagnosis, clinical outcomes, and our understanding of human tumor pathophysiology. 
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Table 1. Distribution of human biopsies stained with SR101 and final diagnosis. SR101 
selectively stained 12 of 11 astrocytoma cases and oligodendroglioma. SR101 did not 
stain necrotic tissue or tumors cells from additionally sampled CNS neoplasms. 
 
Tumor Diagnosis 
Number  
of Cases 
Number  
SR101 Positive 
  Astrocytoma/GBM 
 
13 12 
  Cavernous malformation 
 
4 0 
  Chordoma 
 
1 0 
  Ependymoma 
 
2 0 
  Fibrous dysplasia 
 
1 0 
  Meningioma 
 
17 0 
  Metastasis 
 
6 0 
  Necrosis 
 
3 0 
  Oligodendroglioma 
 
6 1 
  Pituitary Adenoma 
 
5 0 
  Schwannoma 
 
5 0 
  Subependymoma 2 0 
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Table 2. Stereology counts/region of interest.  We quantified colabeling of fixable-
SR101 and antibody staining in tumors with 18 acute slices from 6 rodent xenografts. 
Images were collected from 10 randomly selected 55 μM2 regions of interest optically 
sectioned to 50 μM. 
 
  Tumor Immunostain 
Positive 
SR101 positive Percent Overlap Total Cells 
Counted  
  
Astrocytoma  20.58 ±3.26  22.30±3.55  86.50±1.86  1316 
  Lymphoma  25.61±4.05  1.58±0.32  2.20±0.47  1657  
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CHAPTER 5 
DISCUSSION 
Infiltrative Margin 
 Tumor infiltration is detrimental to improving GBM patient care. Infiltrative cells 
undergo physiological changes which attenuate the effectiveness of current therapeutic 
agents (Horiuchi and Rosenblatt 1987, Wolf, Agnihotri et al. 2010, Wolf, Agnihotri et al. 
2011). Neurosurgery provides a treatment option, with increased extent of tumor 
resection correlating with improved patient survival (Sanai and Berger 2008, Sanai and 
Berger 2009). However, the infiltrative nature of GBM prohibits maximal tumor 
cytoreduction. Developing means for clinically targeting GBM infiltration could improve 
patient survival by- (1) Preventing distal brain parenchymal tumor infiltration, (Barker, 
Prados et al.) allowing greater extent of surgical resection, and (Waring, Steinberg et al.) 
converting GBM into a more manageable chronic disease. Chapter 2 of this dissertation 
evaluates aqp-1 as a protein involved in GBM infiltration, chapter 3 develops a method 
for improving the quality of biobanked GBM patient biopsies, and chapter 4 identified an 
optical contrast agent for improving neurosurgical resection of GBM. Our work fills gaps 
in the current knowledge of GBM by identifying a targetable gene and protein which 
regulate GBM infiltration and developing optical imaging tools for improving GBM 
diagnostics.  
 
AQP1 and Tumor Infiltration 
 Chapter 2 of this dissertation addressed aquaporin-1 and glioblastoma infiltration. 
Aqp1 is a membrane protein discovered by Peter Agre in 1991 (Agre 2006). This protein 
  111 
belongs to a family of channel proteins that regulate cellular water transport. We 
discovered that over-expression of this protein in GBM correlates with decreased patient 
survival. Since the mechanistic role this gene and protein play in cellular motility is 
unknown, our studies address likely mechanisms underlying its prognostic power. 
 We implemented experiments with cultured human GBM cells, and found aqp1 
enhanced the motility of GBM cells in culture without altering proliferation or survival of 
tumor cells. Next, we developed rodent xenografts from human GBM cells over-
expressing AQP1, and found that tumors overexpressing aqp1 produce infiltrative tumor 
margins and decrease animal survival by nearly 20%. This suggests decreased survival in 
GBM patients overexpressing aqp1 is likely mediated by cellular motility.  
 
AQP1 Water Transport and Tumor Motility 
 After observing aquaporin-1 enhanced tumor motility and infiltration in cell 
culture and animal models, we designed experiments testing the role water transport on 
aqp1 mediated GBM motility. We acquired a well-characterized aqp1 mutant (e17n)c 
with one point mutation that effectively prohibits water transport across aqp1’s water 
channel, and generated human GBM cell lines overexpressing the mutant (Yool 2007). 
We found e17n-expressing GBM cells enhance motility similar to wild type aqp1. Our 
animal models confirmed e17n GBM cells produce infiltrative margins similar to wild 
type aqp1.   
 Our findings suggest aqp1 harbors a water transport-independent function that 
enhances tumor infiltration. This is significant to biomedical research as selective 
inhibitors of aqp1-mediated water transport are under development (Yool, Brown et al. 
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2010). Our findings suggest a region of the protein that does not regulate water transport 
must be targeted to modulate aqp1’s role in GBM motility. 
 One potential target is aqp1’s potassium ion transport function. The central pore 
of aqp1, which is created by assembly of 4 aqp1 monomers, transports potassium (Yool 
and Campbell 2012). Recent studies on GBM ion transport have shown that selective 
inhibition of K
+
 decreases motility of GBM cells (Catacuzzeno, Aiello et al. 2011). We 
hypothesize that GBM motility could be attenuated if aqp1-mediated K
+
 transport is 
inhibited. We are currently developing experiments to test this hypothesis.  
 
Reflectance Imaging and Biobanking 
 We identified AQP1 overexpression in clinical biopsies by studying biobanked 
tissue. These tissues are collected and stored by immediately freezing intraoperative 
tumor biopsies (Botling and Micke 2011, Lim, Dickherber et al. 2011, Vaught, 
Henderson et al. 2012, Basik, Aguilar-Mahecha et al. 2013). However, many biobanked 
samples are poor quality (i.e. contain a large amount of necrotic tissue), or do not 
adequately represent the characteristics of the original tumor. This is partially due to poor 
histologic tissue assessment prior to biobanking (Georges, Zehri et al. 2014). We 
hypothesized that a rapid and reliable means for differentiating cellular from necrotic 
samples prior to biobanking could profoundly improve the quality of tissues stored for 
future research.  
 The third chapter of this dissertation develops patient biopsy assessment by 
confocal reflectance microscopy (CRM) prior to biobanking. CRM is an optical imaging 
modality that generates contrast by collecting backscattered photons from an imaged 
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sample. The photons pass through a pinhole that spatially filters photons originating 
outside the focal plane. Since the technique does not rely on a Stokes shift, it requires a 
small fraction of the light energy needed for standard fluorescence confocal imaging 
(Georges, Zehri et al. 2014).  
 Biospecimen analysis by CRM requires stability of tissue DNA, RNA, and 
protein. We generated a time course of samples examined by CRM immediately after 
biopsy to 2 hours post-biopsy. Samples imaged up to 2 hours post-resection had DNA, 
RNA, and protein characteristics similar to reference controls.  
 CRM and DAPI identified similar cellular boundaries in animal glioma models, 
and CRM differentiated cellular from necrotic samples in human biopsies. Interestingly, 
CRM identified several histopathological features utilized for intraoperative diagnoses, 
such as psammoma bodies in meningiomas and antoni A/B regions in schwannomas. We 
are currently testing CRM for intraoperative neuropathologic diagnostics.  
 
Neurosurgery Cytoreduction 
 Surgical tumor cytoreduction is another means for increasing patient survival. 
Studies based on post-operative MRI show optimal survival benefits when at least 98% 
of the tumor is removed (Sanai and Berger 2008, Sanai and Berger 2009, Sanai and 
Berger 2011, Sanai, Polley et al. 2011).  
 Neurosurgeons rely on gross tumor appearance to guide resection during surgery. 
However, GBM is difficult to differentiate from non-neoplastic tissue due to its 
infiltrative nature,  In non-eloquent brain regions, a surgeon may opt for a more 
aggressive resection, possibly resecting benign tissue, in effort to maximize GBM 
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cytoreduction (Sanai 2012).  In more eloquent regions, a surgeon may choose a less 
aggressive course in effort to preserve neurological function. Neuropathologists examine 
frozen biopsy sections from presumed tumor margins intraoperatively to determine 
necessity for further resection. Unfortunately, frozen section contrast agents are not 
tumor-specific and may provide inconclusive feedback.   
 Studies with a tumor-specific contrast agent, 5 ALA, suggest that GBM extent of 
resection increases when neurosurgeons have means to distinguish neoplastic from 
normal brain tissue (Stummer, Novotny et al. 2000, Stummer, Pichlmeier et al. 2006). 
However, this contrast agent is not useful at the microscopic level, and literature suggests 
it may not be tumor-specific (Masubuchi, Kajimoto et al. 2013). We hypothesized that 
the fluorescent contrast agent Sulforhodamine 101 provides real-time intraoperative 
visualization of GBM and its infiltrative margins.  
 
Sulforhodamine 101 
 Clinicians utilize frozen sections and GFAP immunohistochemistry to 
histopathologically diagnose glioblastoma. These histologic techniques were developed 
in the early 20
th
 century, and are fundamentally the same since their inception (Gal and 
Cagle 2005, Powell 2005). Frozen sections are conducted intraoperatively, but can be 
inconclusive due to non-specific staining. GFAP immunohistochemistry provides specific 
staining of GBM, but requires 24-48 hours and is too slow for intraoperative diagnosis.  
In chapter 4 of this dissertation, we begin to develop a novel clinical fluorescent contrast 
agent - Sulforhodamine 101.  We couple the agent  with modern imaging techniques to 
provide immediate cellular visualization of GBM.   
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 SR101 is commonly used in neuroscience research to rapidly label live astrocytic 
cells with GFAP-like specificity (Nimmerjahn, Kirchhoff et al. 2004, Nimmerjahn and 
Helmchen 2012). The work in this dissertation is the first test of SR101’s clinical 
potential. Tested on cell culture, animal brain tumor models, and fresh human biopsies 
we found SR101 could rapidly label astrocytic tumors, such as GBM, with minimal 
labeling of non-astrocytic lesions. Our findings suggest significant clinical potential of 
this fluorescent contrast agent for rapid and specific intraoperative diagnosis. These 
methods could complement current neuropathologic techniques and provide much-
needed information during surgical resection. 
 
Conclusions 
 This dissertation uses interdisciplinary approaches to target the clinical problem 
of GBM infiltration. In chapter two we implemented cancer genomics plus molecular and 
cellular biology to investigate AQP1-mediated GBM patient survival. We began this 
work by analyzing biobanked human GBM biopsies and noticed many biobanked 
specimens lacked the cellularity to be utilized in research. This prompted us to 
successfully develop an optical imaging technique to screen biopsies prior to biobanking. 
Lastly, we identified and tested an intraoperative contrast agent that could improve 
neurosurgical resection of GBM.  
 GBM is the most common primary brain tumor. Despite decades of focused 
research, patient survival has only increased a few months (Salcman 1980, Georges, 
Zehri et al. 2014). The diffusely infiltrative nature of this tumor precludes effectiveness 
of current clinical approaches. By targeting a gene and protein that mediate infiltration, 
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and providing clinicians better tools for intraoperative visualization of GBM, we hope 
this dissertation is a foundation for future translational approaches aimed at improving 
GBM patient care. 
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